STUDIES TOWARDS THE TOTAL SYNTHESIS OF VIRIDENOMYCIN by MOSA, FATHIA,A.
Durham E-Theses
STUDIES TOWARDS THE TOTAL SYNTHESIS
OF VIRIDENOMYCIN
MOSA, FATHIA,A.
How to cite:
MOSA, FATHIA,A. (2012) STUDIES TOWARDS THE TOTAL SYNTHESIS OF VIRIDENOMYCIN.
Doctoral thesis, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/3447/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-profit purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Office, Durham University, University Office, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
  
 
 
 
  
 
 
 
 
 
 
 
Fathia A. Mosa 
 
A Thesis submitted to the University of Durham for the 
degree of Doctor of Philosophy 
 
 Department of Chemistry  
2011 
 
 
Supervisor: Prof. Andrew Whiting 
 
STUDIES TOWARDS THE TOTAL SYNTHESIS OF 
VIRIDENOMYCIN 
 
  
Abstract 
 
Viridenomycin is a very important antibiotic, which showed strong inhibitory activity 
against gram-positive bacteria and an active agent against B16 melanoma. In this work we 
confirmed the asymmetric and stereoselective synthesis of tert-butyl(1R,3Z,5E,7E,10RS)-
10-hydroxy-1-phenylundeca-3,5,7-trienylcarbamate as the key building block towards the 
synthesis of the southern polyene section of viridenomycin. In this synthesis, a series of 
reactions were carried out, including Heck-Mizoroki couplings, Suzuki-Myuara couplings, 
deprotection of the silyl ethers, selective oxidation and enol-acetylation. In addition, the full 
explanation for regeoselectivity of hydroboration with catecholborane on terminal alkynes 
was introduced. Also, our efficient iododeboroation methodology was applied to the 
alkenyl hindered boronate ester and led to the terminal (E)-alkenyl isomer which was the 
only isomer obtained. Therefore, this iododeboronation will be a very important method for 
practical use to prepare highly stereoselective terminal (E)-alkenyl iodide. Moreover, 
selective cleavage of tert-butoxycarbonyl (Boc) for the deprotection of the corresponding 
triene was studied. In addition, two mild cleavage protecting groups (TFAA, phthalimide) 
are studied. In conclusion, we have demonstrated an efficient methodology and a ﬂexible 
approach to the synthesis of conjugated (Z,E,E)-triene core of viridenomycin.  
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CHAPTER I 
ONISOPRENOID POLYNENES NATURAL PRODUCTS: 
CLASSIFICATION, BIOACTIVITY 
 
1.1. Introduction 
Natural products have been attractive to research scientists for many years in different 
areas, such as drug discovery, industrial applications or synthetic studies. Some of the 
richest sources of natural products are marine microorganisms such as bacteria, 
cyanobacteria, dinoflagellates, etc. as the real producers of a variety of bioactive 
substances.
1 “Natural products are both a fundamental source of new chemical diversity and 
an integral component of today's pharmaceutical compendium.”2 More than 13000 
bioactive metabolites have been reported.
3
 However, interest in the discovery of natural 
product drugs has declined, partly due to the diminishing returns from traditional resources 
such as soil bacteria.
2 The polyenes are defined as “a class of natural products that are 
known as potent antifungal and antibacterial compounds.”4 Most of the polyene natural 
products contain a macrolactone ring with several conjugated or unconjugated double 
bonds. The conjugated double bonds are responsible for the physical and chemical 
properties of the compounds (photolability, strong ultra violet/visible light absorption and 
low solubility in water).
5
 The polyenes are also known to be “inhibitors of a number of 
enzymes, such as cholesterol acyltransferase”.4 Moreover, polyenes are an important group 
of natural metabolites produced by multi-functional enzymes in a process that resembles 
fatty acid biosynthesis.
6
 However, while in the biosynthesis of fatty acids, each step is 
  3 
followed by further extension of the complete sequence of reactions, including keto-
reduction, dehydration and reduction. However, in the synthesis of polyenes and other 
macrolides, each product may be subject to all, some or none of the above reactions.
7 
Recently, polyene antibiotics have been received growing interest because of their strong 
biological activities.
8 Until now, more than 200 polyenes produced by Streptomyces species 
have been confirmed together with their biological activities.
8  
 
1.2. Classification of nonisoprenoid polyenes according to chemical structure 
  The polyene natural products are classified according to the number of conjugated double 
bonds which they possess because these conjugated double bonds form a chromophore that 
is responsible for their physical and chemical properties.
5,9
 Each of the different groups of 
polyenes will be considered in the following sections. The effect of the conjugated double 
bonds on their biological activity has been studied, for example, recent research has 
reported the effect of fatty acids with more than two conjugated double bonds on tumor 
cells, demonstrating that “the antitumor effect was superior when the amount of conjugated 
double bonds in a fatty acids polyene chain was higher.”10 Furthermore, conjugated polyene 
construction is considered by chemists to be an important structural feature of many insect 
pheromone components, alarm system of seaweeds and components of the female sex 
attractant.
11
 In this overview, the polyene natural products are divided according to the 
number of the conjugated double bonds i.e. trienes, tetraenes, pentaenes, hexaenes and 
heptaenes. 
 
 
  4 
i. Trienes. 
This group consists of the different types of polyenes which contain three conjugated 
double bonds. The existence of a triene moiety is important for biological activities in many 
trienes. Conjugated trans-triene polyene systems are found in many insect pheromones, for 
example, undeca-(1,3E,5E)-triene 1, nona-(1,3E,5E)-triene 2 and octa-(1,3E,5E)-triene 3 
are sex-pheromone components of some of the marine brown algae species.
11
  
 
 
Figure 1.10 Some trans-triene polyene systems found in insect pheromones. 
 
The (E,E,E)-triene ansamycin antibiotics are a very important class of the ansamycin family 
since they have powerful biological activities, such as antibacterial, antifungal and 
antitumor agents.
12
 The (E,E,E)-triene ansamycins are characterized by a 21-membered 
macrolactane ring with four stereocenters and an (E,E,E)-triene that plays an important role 
in their biological activities.
13,14,15
 The ansamycin compounds include the ansatrienins (or 
mycotrienins),
14,15
 trienomycins,
14
 thiazinotrienomycins
14 
and cytotrienins.
14,16
  
  5 
 
Figure 1.11 Structures of related ansatrienin antibiotics. 
Mycotrienins are a class of compounds that belong to the benzoquinone ansamycins such as 
naturally-derived mycotrienin I 4 and II 5 (Figure 1.11), isolated from Streptomyces 
rishirensis.
14
 They are useful as inhibitors of osteoclastic bone resorption, “marble bone 
disease,”17 and they also possess potent antifungal activity.14 Mycotrienols I and II (Figure 
1.11) were produced with mycotrienins I and II by Streptomyces rishiriensis T-23.
14
 
  6 
Another study including 12-triene ansamycin showed that these trienes, such as 
mycotrienin I 4,  inhibited endoplasmic reticulum stress-induced XBP1 activation.
18,19 
 
 
Figure 1.12 Structures of ansatrienin antibiotics (+)-thiazinotrienomycins A-E.
 
 
Trienomycins A-F (Figure 1.12) were isolated from many Streptomyces sp. These 
compounds showed strong activity in vitro against HeLa S3 cells.
14,20 
Ansatrienin 
antibiotics, (+)-thiazinotrienomycins A-E 18-22 (Figure 1.12), isolated from  Streptomyces 
sp. MJ672-m3, have important activity in vitro against tumor cells from the cervix, stomach 
  7 
and breast.
21
  The mode of action of thiazinotrienomycin is to inhibit membrane transport 
of thymidine and uridine.
21 
The (E,E,E)-triene cytotrienins A-D 23-26 (Figure 1.13) are found in Streptomyces sp. 
RK95-74.
12
 Those ansamycins possess an unusual aminocyclopropane carboxylic acid side-
chain and cytotrienins A 23 and B 25 are potent causative agents of apoptosis in human 
leukemia HL-60 cells.
12 
The total synthesis and the biological activity of cytotrienin A 23 
has been reported.
16 
Moreover, there are (E,E,E)-triene conjugate chromophores in 
amphidinols (AMs) which are a class of polyhydroxy polyene compounds isolated from 
various marine dinoflagellates that belong to Amphidinium species. These mainly consist of 
a linear polyene-polyhydroxyl structures and show potent antifungal activity that 
significantly exceeds that of commercial drugs.
22 
 
 
Figure 1.13 Structures of cytotrienins A-D. 
 
Amphidinols (Figure 1.14) show strong membrane-permeabilizing effects in the form of 
antifungal and hemolytic activity relative to their specific structural characteristics.
21 
The 
  8 
mode of action of these compounds can be explained by forming bio-membrane pores or 
lesions as a result of penetration of the polyolefin (hydrophobic) moieties of AMs into 
membrane lipids and the formation of channels lining with polyhydroxyl (hydrophilic) 
parts.
23
 In addition, the bilayer membrane pores cause disruption of electrochemical 
processes which lead to cell swelling, osmolysis and death.
23,24 
Amphidinol 3 29 has strong 
antifungal and hemolytic activity.
2 
Figure 1.14 Structures of (E,E,E)-triene amphidinols. 
 
 
 
 
  9 
 
 
Another important example of conjugated (E,E,E)-triene polyenes are the manumycins 
(Figure 1.15), which represent a group of compounds with antibiotic, cytotoxic and other 
  10 
biological features. Manumycins are usually isolated from Streptomyces species
26
  and 
manumycin A, C, D, E 41-44 are potent and selective inhibitors of farnesyl transferase in 
vitro and in vivo.
26
 Several manumycins act as inhibitors of interleukin-1 converting 
enzyme, making them potential lead structures for the development of anticancer and 
antiinflammatory agents.
27,28,29
 Asukamycin 45 is an antifungal agent and a potent inhibitor 
of rasfarnesyl-protein.
28
 It also inhibits the growth of Gram-positive bacteria including 
Nocardia asteroids.
28,30,31,32
 Alisamycin 46 has an antibiotic, antitumor and antiparasitic 
action.
28,33
 
 
Figure 1.15 Structures of some manumycins family. 
 
  11 
 
 
 
 
Chinikomycins A 47 and B 48 have been isolated recently from a marine-derived 
Streptomyces species.
34
 Chinikomycin A 47 revealed selectivity against the spread of cell 
lines of breast cancer, melanoma and renal cancer.
26,31
 Chinikomycin B 48 showed 
selective activity against tumor cell line breast cancer.
26,31 
 
The most important of the (E,E,E)-triene polyene macrolide antibiotics is rapamycin 
(sirolimus, rapamune) 49 and its derivative compounds. Rapamycin 49 is a lipophilic  
  12 
macrocyclic antibiotic macrolide produced by the soil bacteria Streptomyces hygroscopicus 
and it is widely used as an immunosuppressant and it used in the treatment of 
cardiovascular, autoimmune and neurodegenerative diseases.
35,36,37 
These compounds are 
currently the most selective kinase inhibitors known and the only inhibitors of mTOR 
(mammalian target of rapamycin) associated kinase activity.
37,38 
Rapamycins bind 
cyclophilin FKBP12 and this complex binds and inhibits the function of mTOR; a serine–
threonine kinase.
37,38 
 
 
Rapamycin 49 inhibits vascular smooth muscle cell proliferation and 
migration
  
and inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic 
pathways.
39,40 
Rapamycin also inhibits lymphocyte proliferation, neovascularization and 
fibrosis.
41 
 
Figure 1.16 Structures of rapamycin 49 and demethoxyrapamycin 50. 
 
Hong-Nong et al. recently reported the isolation of a nonmacrolide polyenic compound, the 
(E,E,E)-triene prorocentin 51, from marine dinoflagellate, Prorocentrum lima.
42
 This 
polyene possesses an all-trans-triene moiety and an epoxide, as well as the 6/6/6-trans-
  13 
fused/spiro-linked tricyclic ether rings. Prorocentin 51 inhibits human colon 
adenocarcinoma DLD-1 and human malignant melanoma RPMI7951.
42 
 
 
 
Figure 1.17 Structure of prorocentin 51. 
 
The (E,Z,E)-triene side-chain was characterized in the natural enantiomer of (−)-exiguolide 
52 (Figure 1.18) which was isolated from the marine sponge Geodia exigua.
43 
 
Figure 1.18 Structure of (-)-exiguolide 52. 
A similar conjugated (Z,Z,E)-triene was found in phostriecin 53, sultriecin 54 and cytostatin 
55.
44
 These compounds were identified as antitumor antibiotics when isolated from 
Streptomyces sp.
44 
  14 
 
Figure 1.19 Structures of some conjugated (Z,Z,E)-trienes. 
 
The (E,E,Z)-triene side chain was characterized in natural leukotriene metabolites, that can 
be used to treat asthma and bronchitis. Two of the important leukotrienes are resolvin E1 56 
and leukotriene 57.
45,46 
Furthermore, there are studies on leukotrienes which have 
confirmed the cis,trans,trans-conjugated triene geometry, and that this was responsible for 
the biological activity of  leukotrienes.
46  
 
 
Figure 1.20 Structure of some conjugated (Z,E,E)-trienes. 
 
 
 
  15 
ii. Tetraenes 
As can be seen from Table 1.10, there are many compounds containing the tetraene moiety 
and which were isolated from different natural sources with full structural assignment and 
stereochemistry determined.  
 
Table 1.10 Examples of some important tetraenes (See structures in Figure 1.21). 
Tetraene Name Producing Organism Biological Activity 
Amphotericin A  
58 
S. nodosus Antifungal activity.
47 
Nystatin 59 S. albulus 
S. noursei 
S. nodosus 
It possesses a potent broad-
spectrum antifungal action.
48 
Antimalarial activity.
49
 It inhibits 
herpes simplex virus I (HSV) and 
HSV II infections.
50
  
Pimaricin 60 
(Natamycin) 
 
S. natalensis 
S. chattanoogensis 
S. gilveosporus 
It used as a natural preservative in 
food industry.
51 
The treatment of 
fungal keratitis, and cutanous, 
vaginal and intestinal candidiasis.
52
  
Antimalarial activity.
49
  
AB-400 61 Streptomyces sp. RGU5.3, Antifungal activity.
53 
Rimocidin 62 
 
S. rimosus 
S. diastaticus 
Antifungal activity.
54
  
Rimocidin B 63 
and C 64 
S. diastaticus Antifungal activity.
55 
CE-108 A 65, B 
66 and C 67 
S. diastaticus var. 108 
 
Antifungal activity.
56 
Lucensomycin 
(Etruscomycin) 
68 
S. lucensis 
 
Antifungal activity.
57 
Arenomycin B 
69 
A.tumemacerans. 
Var.griseoarenicolor 
Antifungal activity.
58 
Tetrin A
59
 70 and 
B
60
 71 
Streptomyces sp. Antifungal activity.
59,60 
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Tetrin C 72 Streptomyces sp. GK9244 Antifungal activity against 
Mortierella ramannianus.
61 
Tetramycin A 73 
and B 74 
S. noursei var. jenensis 
 
Antifungal activity.
62 
Viridenomycin 
75 
S. gannmycicus and S. 
viridochromogenes 
 Antifungal, antibacterial and anti-
tumour.
63
 
Polifungin 76 S. noursei var. polifungini Antifungal activity.
64 
Fumigillin 77 Aspergillus fumigates 
 
Amebicidal, anticancer, 
antiparasitic and antibacterial 
properties.
65,66 
Angiogenesis 
inhibitor.
66 
Lajollamycin 78 Streptomyces nodosus Antimicrobial and antitumour 
activities.
67 
Superstolide A 79 Neosiphonia superstes Highly cytotoxic against several 
cancer cell lines.
68 
 
 
Figure 1.21 Structures of some important tetraenes. 
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iii. Pentaenes 
  Many polyenes are characterised by the existence of a pentaene chromophore and they are 
intrinsically fluorescent. Table 1.11 gives examples of some important pentaenes. 
Table 1.11 Examples of some important pentaenes (See structures in Figure 1.22). 
Pentaene name Producing organism Biological activity 
TPU-0043 
(Chainin)
 
80 
Streptomyces sp. TP-
A0625. 
Chainia 
minutisclerotica 
Antifungal activity.
 69,70, 71 
Filipin III 81 S. filipinensis Antifungal
72 
and antimalarial activity.
 49 
Fungichromin 
82 
(Pentamycin) 
(Cogomycin) 
(Lagosin) 
(Cantricin) 
(Moldcidin B) 
S. padanus PMS-702,  
S. cellulosae 
S. roseoluteus 
S. fradiae 
S. griseus 
 
Strong antifungal activity against R. solani 
AG-4 and it is considered as an active 
ingredient for the control of Rhizoctonia 
damping-off of cabbage.
73 
Aurenin 83 Actinomyces            
aureorectus 
Antifungal activity.
9 
Roflamycoin 
(Flavomycoin) 
84 
Streptomyces 
roseoflavus 
 
Antifungal activity.
74 
 
RK-397 85 Streptomyces sp. Antifungal activity, anticancer activity, 
inhibits human leukemia cell lines K-562 
and HL-60 at 50 and 25 ㎍/mL, 
respectively.
75,76,77 
Roxaticin 86 Streptomycete X-
14994 
Antifungal activity.
78 
Mycoticin A 87 
and B 88  
Streptomyces sp. It exhibits broad antimicrobial activities 
against filamentous fungi, yeast, and 
bacteria.
79, 80 
Lienomycin 89 Actinomyces 
diastatochromogenes                
var. lienomycini 
Antifungal activity, antibacterial and 
antitumor.
81 
  21 
Marinisporolide 
A 90 and B 91  
Marinispora sp. Antifungal activity against Candida 
pathogens.
3 
Myxalamide D 
92 and related 
compounds (93 
and 94). 
Cystobacter fuscus 
Myxococcus xanthus. 
 
Antifungal activitiy against the 
Phythopathogenic fungus Phythopthora 
capsici.
82,83,84 
Strevertene A -
G 95-101 
Streptoverticillium sp. 
LL-30F848 
Antifungal activity against 
phytopathogenic fungi.
85 
Eurocidin D 102 Streptoverticillium sp. Antifungal activity against T. vaginalis.
85b
 
Mirabilin 103 Siliquariaspongia 
mirabilis  
Antitumor.
86 
 
Mycolactones A 
105 and B 106 
Mycobacterium 
ulcerans 
Mycobacterium 
marinum   
Highly potent biological activity.
87 
 
Spirangiens A 
104  and B 105 
Sorangium cellulosum 
(strain So ce90)  
Antifungal activity.
88
  
 
 
Figure 1.22 Chemical structures of some important pentaenes. 
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iii. Hexaenes 
  The class of hexaene antibiotics can be divided into two sub-groups on the basis of the 
hexaene chromophore type: 
1. Hexaene macrolides, which are often characterized by 20- to 40-membered lactone 
rings, contain six conjugated carbon-carbon double bonds and often, the lactone 
ring carries a sugar moiety.
58
 Some macrolides contain an aliphatic side-chain, 
optionally carrying an aromatic substituent. Usually, the macrolide ring carries at 
least one hydroxyl group.
58
 The most effective polyenes in this group are 
dermostatins A 108 and B 109 that have drawn attention on the basis of their range 
of biological activities.
89
 The dermostatins (Figure 1.12) have a conjugated 
hexaene-ketone chromophore. 
2. Linear hexaene polyene antibiotics, such as mediomycins A 110, B 111 and 
clethramycin 112, were isolated from Streptomyces mediocidicus ATCC23936 
activity.
90
 These compounds demonstrated a broad spectrum of antifungal in vitro 
activity.
90
 The other hexaenes, such as mediocidin, endomycin, hexaene-80 and 
hexaene-85, have been reported based on only UV absorption data, for these, 
neither isolation nor structural elucidation has been conducted.
 90
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Table 1.12 Examples of some important hexaenes (See structures in Figure 1.23). 
Hexaene name Producing organism Biological activity 
Dermostatins A 
108 and B 109 
 
 
S. virdigreseus 
Thirum. 
Potent antifungal activity against a number 
of human pathogens and deep vein 
mycoses.
89
 Anti-proliferative activity 
against HIV in H9 cells.
89 
Mediomycin A 
110 and B 111 
S. mediocidicus 
ATCC23936. 
Broad spectrum of antifungal activity.
90 
 
Clethramycin 112 S. mediocidicus 
ATCC23936. 
Broad spectrum of antifungal activity.
90 
Etnangien 113 
 
Sorangium 
cellulosum. 
 
Active against range of gram-positive 
bacteria.
91 
Inhibits retroviral RNA and DNA 
polymerases.
92 
 
 
Figure 1.23 Chemical structures of some important hexaenes. 
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v. Heptaenes 
  The most important group in the heptaenes are the heptaene macrolide antibiotics which 
include the antifungal polyene macrolide antibiotic amphotericin B 114 (Fungilin, 
Fungizone, Abelcet, AmBisome, Fungisome, Amphocil, Amphotec) which has a broad 
spectrum of antifungal activity in humans.
93
 The rod-shaped structure of AmB molecule, 
with the polar mycosamine head, the hydroxyl groups on the one side of the macrolide ring 
and the trans-hexaenes polyene fragment on the opposite side, makes it possible to interact 
both with the polar part of the lipid membrane and acyl chains.
93
 Table 1.13 gives examples 
of some important heptaenes. 
Table 1.13 Examples for some important heptaenes (See structures in Figure 1.24). 
Heptaene 
name 
Producing 
Organism 
Biological Activity 
Amphotericin 
B 114 and its 
derivative 
compounds 
115-117. 
S. nodosus Antifungal activity against deep-seated 
mycotic infections
93 
and intracranial fungal 
masses.
94
 Active agent against visceral 
leishmaniasis,
95 
prion infection,
96 
and 
Plasmodium falciparum infection.
97 
It also is 
described for use in treating malaria infections 
in humans and animals.
49
 It inhibits herpes 
simplex virus I (HSV) and HSV II infections.
58
 
It inhibits Hepatitis B virus (HBV) 
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production.
58
 It is used as mouth rinses in oral 
suspension form to treat severe mucocutaneous 
candidal infections in the mouth.
98 
Candidin 118 S. viridoflavus Antifungal activity.
99
 It is used for treating a 
mammalian tumors/cancers.
100 
Mycoheptin 
119 
Streptoverticillium 
mycoheptinicum 
Antifungal activity against the causal agents of 
deep-seated and systemic mycoses and yeast-
like fungi.
101,102
 It is used in the therapy of 
coccidioidomycosis, histoplasmosis, 
cryptococcosis, chromodermycosis, 
blastomycosis, aspergillosis, sporotrichosis and 
candidiasis.
101,102 
Hamycin 120 S. pimprina It has antifungal activity against a wide range 
of pathogenic fungi and has therapeutic 
efficacy in mice infected with a variety of yeast 
and yeast-like and flamentous fungi such as 
Blastomyces dermatidis, C. albicans, 
Cryptococcus neoformans, Histoplasma 
capsulatum, and Aspergillus niger.
103
 It is 
successfully used in the treatment of oral 
thrush, several other clinical forms of 
candidiasis in normal as well as diabetic 
hosts.
103
 It is effective in the treatment of  
various superficial and deep seated mycoses.
103 
Levorin A2 
121 
(candicidin D) 
A. levoris 
S. griseus ATCC 
3570 
Antifungal activity. It possesses the ability to 
inhibit the growth of adenoma prostatae.
104,105 
Partricin A 
122 and B 123 
(Vacidin A) 
S. aureofaciens It possesses high antifungal activity 
(particularly against Camtida albicans) and 
antiprotozoal activity.
106
  
67-121 A 124 
and B 125 
Actinoplanes 
caeruleus 
It is active in vitro against yeast and 
fungi.
107,108 
Perimycin  A 
126 
(synonyms: 
fungimycin, 
NC-1968, 
S. coelicolor var. 
aminophilus 
Antifungal activity. It induces specific 
permeability changes of the yeast plasma 
membrane resulting in the loss of potassium 
ions from the cells ("potassiumleas death").
109 
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aminomycin) 
DJ-400 B1 127 
and B2
 
128 
S. surinam 
 
Antifungal activity.
9,110 
FR-008 129 
(Candicidin) 
S. griseus 
 
Antifungal compound
111
 “plays an important 
role in protecting the fungus gardens of leaf-
cutting ants against pathogenic fungi 
Escovopsis sp.”111 
Trichomycin 
A 130 
S. hachijoensis 
 
It used as a potent clinical drug for the 
treatment of vaginal infections.
112 
 
Figure 1.24 Chemical structures of some important heptaenes. 
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1.3. Correlation between polyene chemical structure and biological activity 
 In general, the biological activity of the polyenes increases as the number of conjugated 
double bonds increases. Hamilton-Miller gave many examples supporting this general rule.
9
 
Furthermore, when several natural product tetraene macrolides and their derivatives were 
compared with the heptaene macrolide (amphotericin B) in their biological activities on 
Trypanosoma cruzi, these compounds were less effective, but also less toxic.
113
 Kotler-
Brajtburg et al.
114
 attempted to correlate the chemical structures of polyenes and their 
biological properties and they classified polyenes into two groups according to their ability 
to cause K
+
 leakage and cell death. Group I included trienes, tetraenes (pimaricin 60 and 
etruscomycin 68), pentaenes (chainin 80 and filipin 81) and one hexaene (dermostatin 108), 
while group II included the heptaenes (amphotericin B 114, amphotericin B methyl ester 
115, N-acetylamphotericin B 116, hamycin 120 and candicidin 129).
114
 Group I antibiotics 
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caused K
+
 leakage and cell death or hemolysis at the same concentrations of added polyene, 
while group II caused considerable K
+
 leakage at low concentrations and cell death or 
hemolysis at high concentrations.
114
 Furthermore, this classification is supported by 
Akiyama et al.,
115
 who also classified polyene antibiotics according to their synergistic 
effect on fungi into two groups: a non-heptaene group (pimaricin 60, filipin 81 and 
pentamycin 82); and a heptaene group (amphotericin B 114 ).
115
 Moreover, in a study 
regarding the correlation between the size of the polyene antibiotic chromophore and their 
biological effects on fungi (Saccharomyces cerevisiae), Brajtburg et al.
116
 found that large 
polyene antibiotics (amphotericin B 114, hamycin 120, candicidin 129 and the semi-
synthetic derivatives of these) caused both a reversible inhibition of Saccharomyces 
cerevisiae growth and a killing of the yeast cells, whereas small polyene antibiotics (<7 
double bonds in their macrolide rings such as pimaricin 60, etruscomycin 68, chainin 80, 
filipin 81 and dermostatin 108) did not induce the reversible inhibition.
116
 Recently, in a 
study on effect polyene macrolides on the vacuole disruption (S. cerevisiae), it was found 
that the heptaenes are more effective than pentaenes and tetraenes.  
 
1.4. Polyene mode of action 
  The first experiments that shed light on the mode of action of antifungal polyenes were 
implemented in late 1950.
118
 It was shown that these polyene antibiotics interacted with 
specific lipids in the cell membrane of a sensitive organisms.
118
 “All organisms susceptible 
to polyenes, e.g. yeasts, algae and protozoa, contain sterols in their outer membrane,”119 
whereas bacteria that are not affected by most polyenes do not have sterols in their cell 
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membrane. In contrast, fungi are sensitive to polyenes because they have sterols in their 
membrane and it has been suggested that the effect of polyene antibiotics are limited to the 
fungi that have sterols in the composition of their cell membrane.
118,119  
Furthermore, the 
activity of polyene antibiotics is related to their ability to form micelles with the ergosterol 
in the cell membranes of fungal cells.
98 
As a result of this binding, structural damage and 
membrane permeabilisation occurs leading to loss of electrolytes and other components 
such as cytoplasmic proteins;
98
 “As a consequence of which the fungal cells die.”98 
However, it has been reported that polyene antibiotics have the ability to form pores in the 
fungal cell membrane completely lacking sterols.
118
 “In spite of this, the formed channels 
are not responsible for their antifungal activity.”118,119 For example, the mechanism of 
action of amphotericin B is based on interaction with bio-membranes, however, the exact 
binding properties of antibiotics in lipid membranes is still unclear.
120
 There is a full 
discussion
 
of polyene mechanisms in a review by Ghannoum and Rice.
119 
 
1.5. Conclusion 
The polyenes are classified according to the number of conjugated double bonds to trienes, 
tetraenes, pentaenes, hexaenes and heptaenes. Many studies have explained that there is a 
correlation between the size of the polyene antibiotic chromophore and their biological 
effects, however, their mechanism of action still remains obscure.  
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Chapter II 
Studies towards the total synthesis of viridenomycin 
2.1. Introduction 
Viridenomycin 75 is attracting much attention as a total synthesis target because of its 
potent biological activities and complex molecular architecture. Viridenomycin 75 (Figure 
2.10) was first isolated from the culture broth of Streptomyces viridochromogenes strain 
No. T-24146 in 1975 as a weakly acidic and lipophilic substance, which showed strong 
inhibitory activity against Trichomonas vaginalis and gram-positive bacteria.
121
 In 1991, 
this compound was isolated from the culture broth of Streptomyces gannmycicus as an 
agent for prolongation of the survival periods of mice infected with B16 melanoma and 
some fungi.
122,123
 Structurally, it consists of a fully substituted cyclopentene ring, a phenyl 
group and 24-membered  macrocyclic polyene lactam.
123
 The structure of viridenomycin 75 
was established except for the absolute configuration and the relative configuration at C-
25.
123,124 
 
Figure 2.10 Structure of viridenomycin 75. 
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2.2. The aim of the project. 
 This study is mainly aimed at developing suitable methodology for the synthesis of the 
southern unit of viridenomycin 75 (C16-C23), as an important step to complete the synthesis 
of the polyene macrolactam viridenomycin 75.  
2.3. Previous work. 
  The significant antifungal and antitumor activity of viridenomycin and its uniquely 
complex structural features have caused it to become a prime synthetic target within the 
group since 2009. To our knowledge, there are no studies reporting the total synthesis of 
this interesting antibiotic, however, several groups have reported their attempts,
125
 or the 
synthesis of different parts of the structure,
126
 including ourselves.
127,128
 Our group has 
successfully defined a pathway for the convergent construction of the fully substituted 
cyclopentane unit
127a
 131, the northern tetraene section [(Z,Z,E-)-trienyl iodide 132]
127b
 and 
the synthesis of (Z,E)-dienyboronate ester
127c
 133 as an important step towards synthesis of 
the southern section of viridenomycin.  
Figure 2.11 Previous synthesized structures of viridenomycin 75 within the group.
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2.4. Our Synthetic Strategies  
i. Retrosynthetic Plan 
  To approach the viridenomycin 75 structure, the molecule was initially divided into three 
primary fragments, as explained in Scheme 2.10. 
 
Scheme 2.10 Initial retrosynthetic analysis of viridenomycin 75 
  
 
 
ii. Retrosynthetic strategy to construct of the C16-C23 chain (southern 
hemisphere tetraene of viridenomycin). 
 The initial retrosynthetic plan for the synthesis of southern hemisphere (C16-C23) is shown 
in Scheme 2.11. In the retrosynthetic plan, the triene 136 was disconnected at the C4-C5 
bond, which presents a convenient cleavage point for a convergent coupling of 
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dialkenylboronate ester 137 and the (Z)-alkenyl iodide 138.  
 
 
Scheme 2.11 The initial retrosynthetic plan for the synthesis of southern hemisphere 137 
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The intermediate 138 can then be retrosynthetically broken into two segments; the (E)-
alkenyl iodide 140 and a suitable vinylboronate ester 141. The (E)-alkenyl iodide 140 could 
then be transformed cleanly by a stereoselective iododeboronation of the (E)-
alkenylboronate ester 142. Whereas, the (Z)-alkenyl iodide 139 could be obtained from the 
chiral aldehyde 144 and a Wittig reaction using the ylide derived from salt 145. 
 
iii. Enol-lactonization  
 Viridenomycin 75 is characterized by the existence of an enol-lactone moiety, hence, the 
ketone 136 is required for an enol-lactonization reaction. It was, therefore, necessary to 
understand the ability of ketone 136 to undergo enolisation, followed by trapping as an 
activated ester derivative; this is one of the key steps in the retrosynthetic analysis, and 
hence, towards the total synthesis of viridenomycin 75. In order to tackle this reaction, it is 
necessary to survey the known methods for enol-lactonization. 
 
iv. Methods for enol-ester formation 
 Enol-ester lactonization is usually achieved by the reaction of an enol derivative with an 
activated carboxylic acid derivative to afford the enol-ester lactone moiety. There are many 
examples of suitable acylating agents, generally derived from the activation of acids by 
thioesters,
129
 cyanuric chloride 149,
130
 1-methyl-2-chloropyridinium iodide 151,
131
 2,4,6-
trichlorobenzoyl chloride 155,
132
 2-methyl-6-nitrobenzoic anhydride (MNBA) 157,
133 
phosphorous reagents
134
 or carbodiimides.
135
 Mixed anhydrides can also be used to activate 
the carboxylic acid functions, for example, with trifluoroacetic anhydride (TFAA), acetic 
anhydride (Ac2O) and di-tert-butyl pyrocarbonate (Boc2O).
136
 Table 1 provides a list of the 
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activating reagents that can be used for the carboxylic acid moiety the potentially access 
enol ester systems. 
 
Table 2.10 Examples different acid activating agents for carboxylic acids 
Activating reagent for the carboxylic 
acid 
Activated form of the carboxylic 
acid (RCOOH) 
Ref. 
  
129 
  
130 
 
 
131 
 
 
 
132 
  
133 
 
  
134 
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There are few examples of the activation of ketones via the enol for derive enol esters in the 
total synthesis of natural products. The most important and relevant example for the 
formation of an enol ester was introduced by Meyers et al.
125a,125b 
who modified the 
Yamaguchi macrolactonization as a part of their studies towards viridenomycin 75 (Scheme 
2.12). 
 
Scheme 2.12 Enol-esterification using Yamaguchi reagent 155. 
 
 Despite of some studies on enol-lactonization, it is clear that it remains a difficult process, 
and therefore, needs to be refined and improved, or new efficient conditions developed.
137
 
The mechanism of enol-esterification from a ketone using a base (generally organic base) 
and an activated form of the acid is shown in Scheme 2.13. The enol-form of ketone B is 
generated in the reaction in situ by the organic base followed by addition of a mixed 
anhydride to obtain the enol-ester D.  
 
Hence, the development of new methods for the synthesis of enol-lactone moiety of 
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viridenomycin 75 may be one of the major are as of study in this project. 
Scheme 2.13 The mechanism of enol-esterifiction using an organic base and an activated 
form of acid. 
 
 
 
2.5. Summary 
The main aims of this research project towards developing a total synthesis of 
viridenomycin and building the southern hemisphere polyene, is therefore, 1) the 
development an efficient route for the southern polyene reaction of viridenomycin 75; 2) to 
develop an efficient enol-esterification reaction suitable for use in the total synthesis; 3) 
examination of suitable N-protecting groups for the benzylic amide function suitable N-
deprotection methods; and 5) the highly stereocontrolled synthesis of the complete southern 
polyene unit to allow construction of natural product building block 136. 
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Chapter III 
Results and Discussion 
 
3.10. Synthesis of the TBS-protected-homopropargylic alcohol 
Our synthetic studies started with the synthesis of a protected hydroxyl polyene derivative 
143 (See Scheme 2.11) in order to access the corresponding hydroboration product 142 and 
then trans-selective iodo-deboronation to afford trans-alkenyl iodide 140 as reshown in 
Scheme 3.10.  
 
Scheme 3.10 Retrosynthetic plan of  trans-alkenyl iodide 140. 
 
 
This was developed starting from TMS-acetylene 164 (Scheme 3.11). Hence, the 
deprotonation of the terminally protected alkyne 164 with n-BuLi according to the method 
of Burchat et al.
138
 was carried out as shown in Scheme 3.11. This was followed by the 
addition of (±)-propylene oxide, assisted by a Lewis acid (BF3.Et2O) to give the desired 
alcohol 165.
139
 The hydroxyl group was protected by silylation with tert-
butyldimethylsilylchloride (TBSCl) to give the silyl ether 166. Subsequent removal of the 
alkyne protecting silyl group with methoxide gave the terminal alkyne 167 (Scheme 
3.11).
140
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Scheme 3.11 Reagents and conditions: (a) n-BuLi (1.05 eq), Et2O, -75 °C, 30 min, then 
(±)-propylene oxide (1.0 eq), and further addition of BF3·Et2O (1.0 eq) in 2h, -75 °C, 85%; 
(b) TBSCl, imidazole, DCM, 20h, 0 °C to rt, 81%; (c) K2CO3 (1.1 eq), MeOH, rt, 48h, 
89%. 
An alternative method to prepare the terminal alkyne 167 (Equation 3.10) was also carried 
out, employing one step from commercially available (±)-4-pentyn-2-ol 168, however, this 
reaction (with the conditions: TBSCl, imidazole, DCM, MeCN, 3 days)
141
  was very slow. 
It was also found that if the reaction was left stirring at rt for more than 48 h, the starting 
material was not consumed completely by TLC. 
 
 Equation 3.10 Synthesis of silyl ether 167 
 
 
3.11. Stereoselective synthesis of (E)-vinylboronic ester 171 via catecholborane 
mediated hydroboration of alkyne 167 
 
Brown hydroboration of terminal-alkynes with catecholborane usually yields products 
derived from stereospecific cis-addition or syn-addition, with the boron-atom 
regioselectively attached to the least hindered carbon-atom of the triple bond.
142  
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However, the hydroboration of alkyne 167 with catecholborane (Scheme 3.12) gave a 
mixture regioisomeric products 169 and 170, which followed by treatment with 2-
methylpentane-2,4-diol in the presence of base (NaHCO3) gave the desired product 171 as a 
mixture with 172 (See Figure 3.10).  
 
Scheme 3.12 Hydroboration of alkyne 167 
 
 
The consumption of alkyne 167 by the hydroboration with catechol was readily observed 
by 
1
H-NMR which showed the lack of complete regiocontrol resulting in a 1:8 ratio of 
adducts 169 and 170, respectively. After transesterification, the desired product 171 was 
isolated using silica gel chromatography in good yield (91%) together with the regioisomer 
172. The boronate ester 171 was more stable than boronate ester 170 being more readily 
purified and handled. Compound 170 decomposes completely even in the nmr tube 
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presumably due to facile hydrolysis.  
 
Figure 3.10 
1
Hnmr of compound regioselectivity product 172 
 
 
It was concluded that, despite many literature
142 
reports that catecholborane gives high 
regioselectivity to place the boron atom preferentially at the terminal position, we found 
that the hydroboration with catecholborane proceeded with a lack of regiocontrol and this 
may be due to the unhindered nature of the triple bond at substrate alkyne 167. The 
existence of regioisomer 172 was easily detected by 
1
H-nmr as shown in Figure 3.10. 
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3.12. Iodo-deboronation  
Subsequent stereoselective iodo-deboronation of 171 by initial treatment with sodium 
methoxide before the addition of the ICl should provide the E-alkenyl iodide 173 as a major 
product under conditions previously reported.
127a
 Unfortunately, substantial amounts of the 
(Z)-isomer 174 were produced with these conditions (Equation 3.11) as explained in Table 
3.10. The second step, which involved the addition of ICl was carried under low 
temperature conditions (entries 1, 2 and 3) and room temperature condition (entries 4 and 
5). However, this did not improve the stereocontrol in the formation of alkenyl iodide 173. 
 
Equation 3.11 Iodo-deboronation of boronate 171 
 
Table 3.10 Iodo-deboronation of boronate 171 under different conditions. 
Entry Substrate 
(grams) 
Conditions (173:174) or 
(E:Z) 
Yield 
1 2.0 NaOMe (1.2 eq), MeOH, rt,  30 min, then, 
ICl, THF,  -78 ºC, 1h. 
6:1 72 % 
2 10.0 NaOMe (1.2 eq), MeOH, rt, 30 min, then, 
ICl, THF, -78 ºC, 2h.  
3:1 48 % 
3 1.0 NaOMe (1.2 eq), MeOH, rt,  30 min, then, 
ICl, THF,  rt, 30 min, 0 ºC 
3:1 59 % 
4 1.0 NaOMe (1.2 eq), MeOH, rt,  30 min, then, 
ICl, THF,  rt, 30 min 
3:1 68 % 
5 1.0 NaOMe (1.2 eq), MeOH, rt,  30 min, then, 
ICl, THF,  rt, 10 min, 
2:1 62 % 
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Therefore, instead of using the highly reactive ICl, the reaction conditions were adjusted by 
using the less electrophilic diiodine. Hence, subsequent stereoselective iodo-deboronation 
of boronate 171 by treatment with sodium hydroxide, followed by the addition of the 
diiodine
143
 provided the (E)-alkenyl iodide 173. This iododeboronation method (Equation 
3.12) is the first application of this approach on a hindered alkenylboronate ester 171 and 
provides high stereoselectivity (100%) for the (E)-alkenyl iodide 173 as evideneced the 
1
H 
NMR spectroscopy, which showed a clear 14.4 Hz trans-coupling (Figure 3.11).  
 
Figure 3.11 
1
H NMR of the (E)-alkenyl iodide 173. 
 
 
 
a 
b 
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Equation 3.12 Stereoselectivity synthesis of (E)-alkenyl iodide 173 
 
3.13. Heck-Mizoroki couplings 
 Having prepared trans-alkenyliodide 173, Heck-Mizoroki couplings with the commercially 
available vinylboronate 174 were attempted under optimized Heck-Mizoroki reaction 
conditions [silver(I) acetate, catalytic Pd(OAc)2 and tri(o-tolyl)phosphine] which provided 
the dienylboronate 175 in 91% yield and 99% stereocontrol (see Figure 3.12).
127a
 Small 
amounts of the of the Suzuki–Miyaura product 176 were also produced, as shown in 
Equation 3.13. Both products 175 and 176 are separated by SiO2 chromatography due to 
the compound 175 being more polar than 176. 
 
Equation 3.13 Synthesis of boronate ester 175 
 
 
Changing the vinylboronate ester from 174 to 177 under the same optimised Heck-
Mizoroki conditions (Equation 3.14),
127a
 slightly improved the reaction, thus providing 
ester 27 in 93% yield and with less Suzuki-Miyaura product. Fortunately, both (E,E)-
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dialkenyl boronate 175  and 178 had excellent trans-olefin selectivity (>99%) and the 
Suzuki-Miyaura by-product 176 was minimal and readily separated by SiO2 
chromatography. 
Equation 3.14 Synthesis of boronate ester 178 
 
 
 
Figure 3.12 
1
H NMR of the dienylboronate 175. 
 
a 
d b c 
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3.14. Model Compound for Southern Polyene of Viridenomycin 
To study the synthesis and reactivity of the southern hemisphere of Viridenomycin, a 
structure of type 137 was required in order to examine the oxidation and enolization steps. 
In place of this compound, the model compound 179 was suggested (Scheme 3.13) as a 
structure which could be lead to develop our understanding of the behaviour of the southern 
section of viridenomycin 137 in the oxidation  and enolization steps.  
 
 
Scheme 3.13 Model compound 179 for southern part of viridenomycin 137. 
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This model compound 179 was prepared from the reaction between commercially available 
iodobenzene 180 and the dienyl boronate ester 175, which proceeded without incident in 
the presence of [Pd(dppf)Cl2]·CH2Cl2 as catalyst and Ba(OH)2 as base in DMF and H2O at 
room temperature, as shown in Scheme 3.13, and the products were purified by SiO2 
chromatography to give the compound 179 in 71% yield.144 In conclusion, the conjugated 
(E,E)-dienyl aryl system is the preferred product for these Suzuki-Miyaura conditions with 
excellent trans-olefin selectivity. 
The cleavage of the TBS-group of ether 179 was conveniently carried out using 1 M 
tetrabutylammonium fluoride (TBAF) in THF, which gave the corresponding alcohol 181 
(Scheme 3.14) in 74% yield as a yellow solid. 
 
 
Scheme 3.14 Synthesis of the compound 181 
 
 
3.14.1. The decomposition of alcohol 181 
The alcohol 181 was found to be unstable at room temperature even when stored as a solid, 
and thus was preferably kept in the fridge under an inert atmosphere because it decomposed 
at rt in air to give cinnamaldehyde 182, together with other components (Equation 3.15). 
Indeed, a solid sample of alcohol 181 after standing at rt in air was transformed into an oily 
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material. Purification by silica gel chromatography to give both benzaldehyde (24%) and 
cinmaaldehyde (29%) respectivetly together with other mixed and unidentified fractions.  
 
The main reason is possibly that the photo-autoxidate process is likely to cleavage of the 
electron-rich olefins which leads to the decomposition of the whole structure. The 
autoxidation mechanism has been explained before on the basis of the free-radical 
processes.
145a-d 
Equation 3.15 The decomposition of alcohol 181. 
 
 
 
Moreover, the autoxidation of electron-rich substrates under ambient conditions can, in 
general terms, be characterized by α-oxidation (or allylic) oxidation products.145b “With 
unsaturated fats, susceptibility to autoxidation is dependent on the availability of allylic 
hydrogens for reactions with peroxy radicals.”145d 
A suggested mechanism for the autooxidation of 181 (Scheme 3.15) is similar to the 
mechanism of autoxidation of unsaturated fats (linoleate autoxidation).
145d 
 The first step is 
hydrogen abstraction on the reactive allylic carbon of compound 181 by the reaction with 
molecular oxygen, which provides unsaturated hydroperoxide 184. The next step is the 
decomposition of an unsaturated hydroperoxide 184 by the homolytic cleavage of the 
oxygen-oxygen bond to yield an alkoxy 185 and hydroxy radical.
145d 
Carbon-carbon 
cleavages (a) and (b) lead to aldehydes 186 and 183 and olefin radicals 187 and 190, which 
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then react with hydroxy radicals to form enols 188 and 191, and hence tautomerize to the 
corresponding aldehydes 189 and 192 (Scheme 3.15). 
 
Scheme 3.15 Suggested mechanism for autoxidation of alcohol 181. 
 
 
The reaction of molecular oxygen with pentadienyl radical 193 can produce a mixture of 
unsaturated hydroperoxides 194 and 202. The most favourited site for the attacking of 
molecular oxygen is the ends of pentadienyl radical 193 (a and b), as shown in Scheme 
3.16. In the following reaction sequence, the first step of the decomposition of the 
unsaturated hydroperoxides 194 and 202 is the homolytic cleavage of the oxygen-oxygen 
bond to yield alkoxy radicals 195 and 203 and hydroxy radicals.
145d  
Carbon-carbon 
cleavages (a) and (b) provides aldehydes 196 and 183 and olefin radical 187, which then 
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reacts with hydroxy radicals to form 1-enols, which tautomerize to the corresponding 
aldehydes (Scheme 3.16).  
Scheme 3.16 Suggested mechanism for autoxidation of alcohol 181. 
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Another suggested mechanism depends on the sensitivity of electron-rich compounds to 
both air and light (photooxidation). The photosensitized allylic alcohol 181 can be the 
subject of abstract hydrogen by light to give pentadienyl radical 193 (Scheme 3.16). 
In another approach, both unsaturated hydroperoxides 194 and 202 can lose hydrogen to 
lead to the formation of five-membered epidioxides 211 and 214.
145d
 The five-membered 
ring in compounds 211 and 214 can then be reopened and gain a hydrogen radical to give 
unsaturated hydroperoxide 184, which decomposes as explained in Scheme 3.17. 
Scheme 3.17 Suggested mechanism for autoxidation of alcohol 181. 
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3.14.2.
 
Oxidation of allylic alcohol 181 
Unfortunately, attempts to oxidize (Equation 3.16) the alcohol 181 with pyridinium 
chlorochromate (PCC) as a mild oxidizing agent in the presence of sodium acetate led only 
to decomposition (Table 3.11, entry 1).
146a
 The oxidation of alcohol 181 to the ketone 215 
with Dess-Martin periodinane (DMP) without NaHCO3 (entry 2) did not afford the desired 
product either.
146b 
Attempts to oxidize alcohol 181 by activated manganese(IV) oxide and 
potassium permanganate led to over-oxidation of the substrate (entry 3), which could be 
due to the effect of a strongly acidic oxidant potassium permanganate.
146c 
The Swern 
oxidation of alcohol 181 to the corresponding ketone 215 using oxalyl chloride and 
dimethyl sulphoxide (entry 4) provided the desired product, but in low yield (39%) after 
SiO2 chromatography.
146d  
 
 
Equation 3.16 Attempts conditions to oxidize the alcohol 181 to the ketone 215. 
 
Table 3.11 Attempts to oxidize the alcohol 181 to the ketone 215 
Entry Conditions Result 
1 NaOAc (0.08 eq), PCC (2.0 eq), DCM, 2h, rt. Decomposition 
2 DMP (1.1 eq), DCM, 2h, rt. Decomposition 
3 KMnO4 (3.2 eq), MnO2 (17.3 eq), DCM, 3h, rt. Decomposition 
4 (COCl)2 (2 eq), DMSO (4 eq),  DCM, -78 ºC, 10 min, then 
Et3N (5 eq),  -78 ºC to rt. 
39% (keto-enol 
form) 
5 NaHCO3 (3 eq), DMP (2.0 eq), DCM, 2.5 h, rt. 91% 
6 NaHCO3 (3 eq), DMP (1.5 eq), t-BuOH (0.8eq), DCM, 4h, rt. 100% 
 
 
The oxidation with DMP
 
in the presence of sodium carbonate at 0 °C (entry 5) led to the 
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desired product 215 as a main product in 81 % after SiO2 chromatography. The sodium 
carbonate most likely prevents the effect of the by-product acetic acid from causing the 
decomposition of the product 215.
146e
 The best conditions for this oxidation were, therefore, 
obtained for the Dess-Martin periodinane, NaHCO3 and tert-butanol as a catalyst (entry 6) 
providing a quanitative yield after isolation by SiO2 chromatography.
146f
 Table 3.11 
summarizes the conditions which used to oxidize alcohol 181 to ketone 215.  
 
3.14.3. Enol-acetylation of ketone 215 
In order to investigate both the stereselectivity and regioselectivity of enol-esterification in 
conjugated beta-ethylene dienes, such as 215, the reaction conditions were initially 
examined involving a simple anhydride and pyridine. The aim being to model suitable 
conditions for the coupling of a ketone of type 136 with model of an activated acid 
derivative of building block 134. Hence, enol acetylation of ketone 215 with acetic 
anhydride in the presence of pyridine at room temperature led to the desired product 216 
(65%) as a mixture of (E) and (Z)-enolacetates in a 4:1 ratio as shown in Figure 3.13 
(Equation 3.17). The existence of the regioselectivity product 217 was also indicated 
clearly by 
1
H NMR spectroscopy due to the readily observed CH2 resonance at δH 2.31-
2.45 ppm. The regioselectivity of the formation of the enol ester 217 was unexpected since 
the hydrogens in the α-positions next to the dialkenyl aromatic are usually more acidic than 
the α-protons at the methyl group, and hence, the thermodynamically contolled enol-
esterification conditions were expected to produce  216 with higher selectivity.  
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Equation 3.17 Enol-acetylation of ketone 215 
 
 
Figure 3.13 
1
Hnmr of compound 216. 
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3.14.4. Enol-esterification of ketone 215 
As a second, and more advanced, model for the potential coupling acid 134 with ketone 
136, the enol-esterification of model 215 was investigated with phenybutric acid 
derivatives. Firstly, commercial available 4-phenylbutyric acid 218 was as used to test the 
reactivity of ketone 215 towards the synthesis of enol ester 220 (Scheme 3.18). Many 
conditions were used and are summarized in Table 3.12. 
 
Scheme 3.18 Attempts to Synthesis of Enol-ester 220 of Ketone 215 
 
 
Table 3.12 Attempts to synthesis enol-ester 220 of ketone 215 with different conditions 
Entry Conditions Result 
1 215, PPh3 (1.05 eq), DMAP (1.0 eq), DEAD (1.05 eq), 218 
(1.1 eq), THF, rt, 22h. 
SM 
2 215, CDI (1.1 eq), THF, 218 (1.1 eq), rt, 3 days. SM 
3 215, CDI (1.1 eq), DMAP, THF, 218 (1.1 eq), rt, 23h. SM  
4 215, Et3N (3.0 eq), DMAP (10 mol%), toluene, rt, 3h, then, SM 
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CDI (1.1 eq), 218 (1.1 eq), 48h. 
5 215, Et3N (4.0 eq), DMAP (1.0 eq), toluene  
rt, 3h, then, TFAA (4.8 eq), 218 (4.8 eq), 2h.  
222 (33 %), 220 
(5%)  
6 215, pyridine (2 eq), DMAP (10 mol%), toluene, 2h, then 
TFAA (1.1 eq), 218 (1.1 eq), rt, 4h. 
222 (83%) 
7 215, Et3N (3.0 eq), DMAP (10 mol%), toluene, rt, 10 min 
then add mixed anhydride 219 (1.0 eq), 24h. 
222 (24%), 220 
(27%)  
8 215, pyridine (3.0 eq), DMAP (10 mol%), THF, rt, 10 min 
then add mixed anhydride 219 (1.0 eq), 24h. 
220 (29%), 222 
(23%),  
9 215, Et3N (3.0 eq), DMAP (10 mol%), HMPA (0.1 eq), 
toluene, rt, 2h then add mixed anhydride 219 (1.0 eq), 24h. 
220 + 221 (15%), 
222 (57%) 
10 215, Et3N (3.0 eq), DMAP (10 mol%), toluene, rt, 10 min 
then add MNBA (1.1 eq) and 218 (1.1 eq), 16h. 
220 + 221 (45%), 
222 (28%)  
11 215, Et3N (3.0 eq), ZnCl2 (15 mol %), toluene, rt, 10 min 
then add MNBA (1.1 eq) and 218 (1.1 eq), 24h. 
222 (100%) 
12 215, Et3N (3.0 eq), TMSCl (1.05 eq), ZnCl2 (1.0 eq), 
DCM, rt, 4h, then add mixed anhydride 219 (1.0 eq), 23h.  
222 (85%) 
 
 
i- Mitsunobu Reaction (Table 3.12, Entry 1) 
The Mitsunobu reaction is a condensation-dehyration reaction, in which triphenyphosphine 
223 is oxidized to triphenylphosphine oxide 235, and diethylazodicarboxylate (DEAD) 224 
is reduced to hydrazine dicarboxylate 233.
147a
 The synthesis of ester 220 from ketone 215 
by the reaction with 4-phenylbutyric acid 218 in the presence of a catalytic amount of 
dimethylaminopyridine (DMAP) to generate enol system with Mitsunobu reaction 
conditions (entry 1 ) did not lead to the desired product 220.
147a  
The suggested mechanism 
for this type of enol-esterification is explained in Scheme 3.19. 
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Scheme 3.19 Mechanism of enol-esterification wih DEAD 224 as a reagent 
 
 
ii- Application of CDI 236 reagent for enol esterification of  ketone 215 (Table 
3.12, Entries 2-4) 
1,1'-Carbonyldiimidazole (CDI) 236 is often used for esterfication reactions.
147b
 
 
Unfortunately, attempts to apply CDI conditions (entry 2, 3 and 4) for ketone 215 did not 
lead to the desired product 220. The suggested mechanism for this type of enol-
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esterification is explained in Scheme 3.20. 
 
Scheme 3.20 Mechanism of enol-esterification with CDI 236 reagent 
 
 
iii- Application of TFAA reagent for enol esterification of ketone 215 (Table 
3.12, Entries 5 and 6) 
The treatment of 4-phenylbutyric acid 218 with trifluoroacetic anhydride (TFAA) should 
generate mixed anhydride, which added directly to mixture of ketone 215, triethylamine 
and DMAP as a catalyst should form the enol ester 220. Unfortunately these conditions 
(entry 5) led to the desired product 220 in very low yield (5 %). 4-Phenylbutyric anhydride 
222 appeared as a main by-product (entry 6) in 83% in the presence of stoichiometric 
pyridine.  
 
iv- Application of Yamaguchi reagent 155 for enol esterification of  ketone 215 
(Table 3.12, Entries 7 - 9) 
The enol esterification was performed using the Yamaguchi's strategy
174c
 (entry 7). Firstly, 
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the mixed anhydride 219 was synthesized from the commercial available 4-phenylbutyric 
acid 218 and 2,4,6-trichlorobenzoyl chloride (Yamaguchi reagent) 155 (Equation 3.18) and 
then subjected to Yamaguchi's conditions in toluene and THF (entry 7 and 8 respectively), 
which both afforded the desired product 220 (24%) with the symmetrical anhydride 222. 
Using HMPA as the polar solvent and DMAP as catalyst with mixed anhydride 219 (entry 
9) led to a loss of regioselectivity, providing a mixture of products 221 and 221 in ratio of 
4:1 according to 
1
H NMR.  
 
Equation 3.18 synthesis of mixed anhydride 219 
 
 
v- Application of MNBA reagent 157 for enol esterification of ketone 215 (Table 
3.12, Entries 10 - 12) 
On other hand, using 2-methyl-6-nitrobenzoic anhydride (MBNA) 157 with triethylamine 
in the presence of DMAP (entry 10) resulted in the highest increase in the enol ester 221 
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formation as a 3:1  mixture with enol ester 220. Furthermore, using the Lewis acid ZnCl2 as 
a catalyst under the MNBA conditions (entry 11), this gave the symmetric anhydride 222 as 
a main product.
147d
  
 
In another method, the trimethysilyl enol ether of ketone 215 was generated (entry 12) and 
then reacted with mixed anhydride 219, which give the symmetric anhydride 222 (83%). 
As mentioned before, this is the by-product 4-phenylbutyric anhydride 219, which appeared 
as a main product and resulted in high yield as a competitive by-product in several entries 
in Table 3.12, which contributed to the low yield of the desired product 220.  
 
3.14.5. Conclusion: 
The conditions that lead to the by-product, the symmetric anhydride 222 for example, with 
the catalyst ZnCl2, which lead to produce 222 as a major product (entries 6, 11 and 12) 
need to avoided in order to access enol ester derivatives. Using CDI did not afford any 
significant amount of the enol ester (entries 2 to 4). The desired product (E)-enol ester 220 
is the thermodynamic product of enolisation of 215 and the kinetic product is the regio-
isomer enol ester 221, so the conditions, which gave the thermodynamic product 220, are 
required (i. e. no catalyst). The 
1
H NMR of compound 220 as a pure single isomer, which 
obtained by recrystallization using methanol (Table 3.12, entry 7), is explained in Figure 
3.15. Hence the best conditions for the formation of 220 were using the Yamaguchi 
conditions and there (as entry 7, Table 3.12) gave 220 as a single, pure compound in 13% 
yield of the recrystallization from methanol. 
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Figure 3.14 
1
H NMR of compound 220 before crystallisation 
 
Figure 3.15 
1
H NMR of compound 220 after crystallization. 
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3.14.6. Attempts to synthesis of enol-ester 246 of ketone 215. 
As the model of cyclopentene core of viridenomycin (see Scheme 2.10), the commercial 
available cyclopentane carboxylic acid 241 was used for this purpose and to study its 
reactivity towards the enol esterification reaction with ketone 215. 
 
Figure 3.16 Cyclopentane carboxylic acid 241 as a model of viridenomycin core 134. 
 
Using Yamaguchi method, treatment of cyclopentane carboxylic acid 241 with 2,4,6-
trichlorobenzoyl chloride 155 generated the mixed anhydride 242 as a stock solution which 
was used without further purification. 
 
Equation 3.19 Generation of mixed anhydride 242.  
 
 
When mixed anhydride 242 was used to react with the commercial available acetophenone 
243 as shown in Table 3.13 (Entry 1) and Scheme 3.21, no significant for olefinic protons 
corresponding to an enol-ester 244 were detected by 
1
H NMR spectra. The conditions 
(Table 3.13, Entry 2) also did not led to the enol-ester 244. It was concluded that despite the 
simplicity of the structure of enol-ester 244, there is a difficulty in producing this enol ester, 
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because of the conjugated aromatic system which neighbouring for the carbonyl group. 
Moreover, generating carbanion of ketone 243 is difficult and it can react in different ways 
that led to a mixture for undesirable products. It thus seems that the model ketone 215 is 
better than the commercially available acetophenone 243 for the enol-esterification 
reactions. 
 
Scheme 3.21 Attempts to synthesis enol-ester 244 of ketone 243. 
 
Table 3.13 Attempts to synthesis enol-ester 244 of ketone 243 with different conditions. 
Entry Conditions Result 
1 243, pyridine (6.0 eq), DMAP (5 mol%), toluene, rt, 
mixed anhydride 242 (3 eq), 48h. 
No significant to 
olefinic protons by 
1
H NMR spectra. 
2 243, pyridine (6.0 eq), DMAP (5 mol%), MNBA (1.3 
eq), THF, rt, 10 min then add 241 (1.3 eq), < 48h. 
No reaction. 
 
Therefore, the mixed anhydride 242 was generated as the reagent to react (Scheme 3.22) 
with ketone 215 under different conditions (Table 3.14, Entries 1-3). The best conditions 
were obtained from Entry 3 (Table 3.13) with using DMAP as a catalyst, however, the 
problem was how to isolate the desired enol-ester 246 from the mixture of other enol-esters 
and the by-products such as the symmetrical and unsymmetrical anhydrides. By using silica 
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gel chromatography, the desired enol-ester 246 was not isolated. Therefore, working on the 
enol-esterification reaction using this model 215 perhaps needs further studies and the 
development of completely new approaches for enol-esterification reacrions. 
Scheme 3.22 Attempts to synthesis enol-ester 246 of ketone 215. 
 
Table 3.14 Attempts to synthesis enol-ester 246 of ketone 215 with different conditions. 
Entry Conditions Result 
1 215, Et3N (3.0 eq), toluene, rt, 20 min, then 
add mixed anhydride 242 (2 eq), 3days. 
The reaction was very slowly 
and the staring material was 
still present in the reaction after 
3 days. 
2 215, Et3N (3.0 eq), DMAP (10 mol%), 
THF, rt, 10 min then add 241(1.1 eq), 24h. 
Unidentified mixture of enol 
esters (16%) 
3 215, Et3N (3.0 eq), DMAP (10 mol %), 
HMPA (0.1 eq), toluene, rt, mixed 
anhydride 242 (2.0 eq), 24h. 
Unidentified mixture of enol 
esters (60%) 
 
 
3.15. Enantioselective synthesis conditions of alcohol 250 
According to the retrosynthetic plan of the compound 139 (Scheme 3.23), the synthesis 
began with a one-pot reduction-protection of the amino acid 249 using sodium 
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borohydride-iodine then N-Boc protection of the amino group with di-tert-butyl dicarbonate 
in the presense of triethyl amine as base.
148 
This was an efficient, optimized overall process, 
and to our knowledge there are only two other reported examples of a one-pot amino acid 
reduction/N-protection sequence.
149
 Both employ lithium aluminumhydride (LAH) to 
achieve the reduction prior to N-protection with Boc2O, affording the N-Boc-amino 
alcohols in 69–83% yield.149 In all other instances, the amino alcohols, usually obtained via 
LAH, activated borohydride or mixed anhydride reductions, are isolated prior to N-
protection and often extensive aqueous work-ups are required following the reduction 
methods cited leading to diminished yields.
149
 The protocol
148
 employed herein is rapid, 
efficient and readily scaled up.  
 
Scheme 3.23 The retrosynthetic plan of the compound 139 
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During the first phase of this study, our efforts involved attempts to isolate the pure alcohol 
derivative 250 from starting amino acid (R)-phenylglycine 249. The difficulty, which was 
faced, was obtaining a high enantiomeric excess of compound 250 using the two-step 
sequence shown in Equation 3.20. As shown in Table 3.15, several conditions were 
attempted in order to obtain highly enantiomerically pure product 250. Consequently, it was 
found that the best conditions for large scale were from conditions C and small scale 
conditions D (Table 3.15). In conditions D, the reaction was carried out under mild 
conditions by using 2.2 eq of NaBH4 and 2.2 eq of I2, rather than the previous conditions
148
 
in order to minimize the basicity of the reaction medium. Thus, it was found that there was 
a strong effect of basicity on the racemization which decreased as the basicity of the 
solution decreased. Therefore, mild conditions were required to prevent this racemization 
during the reduction of the amino acid, followed by N-protection of amino-group 
(conditions D) which gave enantiopure compound 250.  On the other hand, adding the Boc-
group was attempted under cold conditions (0-5 
°
C) in the second step to prevent further 
racemization (conditions B),  which may result from N-inversion at the secondary NH 
center because of the conversion of amino group under cold conditions is slower than under 
warm conditions. 
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Equation 3.20 Enantioselective synthesis conditions of alcohol product 250. 
 
Table 3.15 Determination of enantiomeric excess of compound 250 by HPLC under 
modification of reaction conditions shown in equation 3.20. 
Entry Reagents and Conditions % yields Enantiomeric 
excess % 
A 1) NaBH4 (2.4 eq),  I2 (1.0 eq), normal THF, 18h, 
reflux; 2) (Boc)2O, Et3N, 3h, rt. 
76 65.7 
B 1) NaBH4 (2.4 eq),  I2 (1.0 eq),  dry THF; 2) (Boc)2O, 
Et3N, 3h, 0-5 °C 
88 63.3 
 C 1) NaBH4 (2.4 eq),  I2 (1.0 eq),  THF (fresh 
distillated), 18h, reflux; 2) (Boc)2O, Et3N, 3h, rt. 
94 ≥99.8 
D 1) NaBH4 (2.2 eq),  I2 (2.2 eq),  dry THF, 18h, reflux; 
2) (Boc)2O, Et3N, 3h, rt. 
72 ≥99.8 
 
 
The amino acid racemization (Scheme 3.24) occurs in a basic (or acidic) medium by the 
formation of the carbanion (enol) intermediate. The base abstracts the α-proton of 252 and 
this is the rate-limiting step in the reaction. Finally, re-addition of the proton occurs 
resulting in racemisation.  
 
 Scheme 3.24 The amino acid racemization in acidic or basic medium. 
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Figure 3.17 HPLC chromatogram of compound 249 using Chiralpak OD column,  = 
235nm, hexane : EtOH (90 : 10) and flow rate = 0.5 mL/min 
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3.15.1. Suggested mechanism of reduction of carboxylic acid by NaBH4/I2  
The mechanistic steps of the reduction involves: first, the iodine reacts with sodium 
borohydride to give borane, sodium iodide, and hydrogen iodide; Then, hydrogen iodide 
reacts with further sodium borohydride which leads to more borane formation and sodium 
iodide plus hydrogen. Thus, it is the borane which reduces the acid to alcohol (Scheme 
3.25).
150 
  
 
Scheme 3.25 Suggested mechanism of reduction of carboxylic acids using NaBH4/I2 
system 
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Moreover, the fact that reactive BH3-THF acts as reducing agent for carboxylic acids is 
clear, yet  the mechanistic explanation of is still ambiguous.
150  
Moreover, in the N-Boc 
protection of amino group step (in Equation 3.20), any existence of iodine, which is 
used in the first step, may assist N-Boc protection of the amino group, as reported 
before and shown in Scheme 3.26.
151
 In this mechanism  and from 
1
H NMR and IR 
studies, coordination of I2 with (Boc)2O in the transition state (W) was suggested.
151 
 
Scheme 3.26 The mechanism for iodine-catalyzed N-Boc protection of amines.  
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3.15.2. Conclusion 
To prevent racemization of phenylglycine to access 250 in the first step of the reaction, it 
was necessary to understand that the first step was very sensitive to the aqueous conditions 
(conditions A and B) and that the solvent should be freshly distillated to prevent any 
racemisation (conditions C and D). Furthermore, it was found that there is an affect of the 
basicity on the scale up of the reaction; the conditions D were applied on small scale and 
there was not any racemisiation, whereas the conditions C was applied on large scale and 
there was not any racemisation. 
  
3.16. Methanesulfonylation (mesylation) of primary alcohol 250 
Methanesulfonylation (mesylation) of primary alcohol 250 (Equation 3.21) was considered 
to be preferred, most preferably using MsCl (methanesulfonyl chloride) and Et3N because 
the mesylate group is considered an excellent leaving group in nucleophilic substitution 
reactions.
148
 Hence, mesylte 254 could be isolated readily and scaled up conveniently to 
give high yields, as shown in Equation 3.21. 
 
Equation 3.21 Mesylation of primary alcohol 249 
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3.17. Cyanation Reaction 
The cyanation reaction of mesylte 254 was carried out as shown in Equation 3.22 using a 
nucleophilic SN2 displacement of mesylate group by cyanide ion, using sodium cyanide in 
DMSO to give 255 in 84% yield.
148 
Many attempts were used to know the good HPLC 
separation system for 255 (Table 3.16) to help to determine the accurate enantiomeric 
excess purity of 255. The best HPLC separation of two enantiomers was HPLC conditions 
in entry 5 (Table 3.16). 
 
Equation 3.22 Cyanation reaction 
 
 
Table 3.16 HPLC conditions using Chiralpak OJ column at  = 254nm.  
Entry Hexane : IPA Flow rate (mL/min) tR of 255 tR of s-enantiomer of 255 
1 70 : 30 0.75 19.79 17.10 
2 90 : 10 0.75 22.91 18.93 
3 90 : 10 1.0 17.34 14.17 
4 95 : 05 1.0 32.52 24.59 
5 95 : 05 0.75 44.37 32.24 
 
Fortunately, both steps (mesylation and nucleophilic displacement by cyanide) were carried 
out under conditions that did not cause racemization, as determined using chiral HPLC. In 
addition, we reported a new system for determining the enantiomeric excess of the cyanide 
compound 255 by chiral HPLC. This showed an e.e. ≥ 99.8% under conditions: Chiralpak 
OJ column, hexane:2-propanol (95:5), 0.75 mL/min and  = 254 nm. 
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3.18. Reduction of nitrile 255 to aldehyde 256 
The reduction of nitrile function of 255 using diisobutylaluminum hydride (Dibal-H) as a 
relatively mild reducing agent under specially developed conditions (Equation 3.23) gave 
the aldehyde 256 in 98% yield.
152 
This aldehyde  256 was purified using flash SiO2 column 
chromatography immediately upon isolation because of its unstability. However, this 
reaction was amenable to scale up and isolation of good quantities of the aldehyde, which 
were used soon after purification. 
 
Equation 3.23 Reduction of nitrile 255 
 
 
 
3.19. Wittig Homologation of aldehyde 256 
The  phosphonium salt 145 was prepared from the reaction of triphenylphosphine 223 with 
diiodomethane (CH2I2) as shown in Scheme 3.27.
153a
 To form the Wittig reagent 
(Ph3P=CHI), the phosphonium salt 145 was suspended in THF and a strong base 
(LiHMDS) in the presence of HMPA was added.
153a
 Olefination of aldehyde 256 with the 
Wittig reagent (Ph3P=CHI, THF; -78 C) generated the (Z)-alkenyl iodide 258.
153a 
Unfortunately, the yield of the desired product, (Z)-alkenyl iodide 258 was low (40%). This 
was due to the problems of removal of the triphenylphosphine oxide (TPPO) 235 is 
removed by silica gel column chromatography due to the similarity polarity between TPPO 
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and (Z)-alkenyl iodide 258. However, despite these issues, the desired (Z)-alkenyl iodide 
258 was isolated in 40% yield (Scheme 3.27) and used in the next step. 
 
Scheme 3.27 Wittig Reaction of Aldehyde 256 
 
 
There is an alternative method to minimize the TPPO quantities by complexation method in 
which the addition of a metal salt to form a complex with the TPPO.
153b
 The copper (II) 
chloride (CuCl2) was used for this purpose but, unfortunately, gave some TPPO by-product 
and, therefore, column chromatography was the most useful purification technique 
compared to the complexation method.’153b 
 
 3.20. Heck-Mizoroki couplings of (Z)-alkenyl iodide 258 
Heck-Mizoroki couplings were attempted under optimized Heck reaction conditions, by 
using vinyl boronate 177, with silver(I) acetate, Pd(OAc)2, tri(o-tolyl)phosphine (Equation 
3.24).
127a
 Fortunately, these conditions led to the desired produce the (1R,3Z,5E)-
dienylboronate 133 in an excellent 73% yield after silica gel chromatography. Importantly, 
there was no sign of any competing Suzuki-Miyaura side-products. 
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Equation 3.24 Heck reaction
 
 
3.21. Rout to synthesize the southern hemisphere of viridenomycin using 
dialkenylboronate 133 
Equation 3.25 Suzuki–Miyaura couplings conditions 
 
 Table 3.17 Different Suzuki–Miyaura couplings conditions. 
Entry Conditions (equivalents) Base 
 (1.2 eq) 
Temp. Solvent Result 
1 133 (1.2), Pd(PPh4)4 (0.05), 173, 48h t-BuOK 67 THF Traces of 259 
in the crude 
2 133 (1.2), Pd(PPh4)4 (0.1), 173, 48h t-BuOK 67 THF Traces of 259 
in the crude 
3 133 (1.2), Pd(dppf)Cl2.CH2Cl2  (0.15), 
173, 24h. 
Ba(OH)2  rt DMF Traces of 259 
in the crude 
4 133 (1.2), Pd(PPh4)4 (0.05), 173, 48h Ag2O 67 THF No reaction 
5 133 (1.2), Pd(PPh4)4 (0.05),  173, 48h Ag2O 80 DMF No reaction 
6 133 (1.1), Pd(OAc)2 (0.05), 
triphenyphosphine (0.1), 173, 48h 
Ag2O 67 THF No reaction  
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Initial attempts at Suzuki–Miyaura couplings were disappointing, the reaction of (Z)-
alkenyl iodide 258 and dialkenylboronate 133 did not lead to give triene 259 under a 
different Suzuki–Miyaura conditions (Table 3.17). Most of these attempts of Suzuki–
Miyaura couplings (Table 3.17) were run on small scale (10 mg) of substrate ((E)-alkenyl 
iodide 173). From 
1
H NMR spectroscopy, the oily crude product contained only traces of 
the desired triene 259 (entries 1 and 2). Unfortunately, these used couplings conditions did 
not give any sign for a good yield of the target triene 259.  
 
3.21.1. Alternative route to synthesize the southern hemisphere of Viridenomycin 
using (Z)-alkenyl iodide 258 
Another route was suggested in order to synthesize the triene core 259 as shown in 
Equation 3.26. In this route, the dienyl boronate ester 175 was reacted with (Z)-alkenyl 
iodide 258 using a Suzuki–Miyaura coupling.  
However, Suzuki–Miyaura coupling between (Z)-alkenyl iodide 258 and the 
dialkenylboronate ester 175 under literature conditions
144
 proceeded without incident in the 
presence of [Pd(dppf)Cl2]·CH2Cl2 and Ba(OH)2 in DMF and H2O at room temperature as 
shown in Equation 3.26, affording the triene 259 in 71% yield after silica gel 
chromatography.  
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Equation 3.26 Suzuki–Miyaura couplings 
 
Moreover, the catalyst used, Pd(dppf)Cl2.CH2Cl2 260 (Figure 3.18), has been shown to be 
an extremely active catalyst for the Suzuki reaction of aryl halides in water.
144
 The
 
large 
bite angle (), as shown in Figure 3.18, helps favor reductive elimination in the Suzuki 
reaction mechanism, while the weakly electron-donating bidentate triarylphosphine ligand 
(dppf) stabilizes the catalytic center due to the rigid and blocked conformation of the 
ferrocenyl backbone.
154 
In addition, a large bite angle of the ligand brings the two organic 
groups closer, promoting the reductive elimination step.
154 
 
 
Figure 3.18 Bite angle () of [Pd(dppf)Cl2]·CH2Cl2 
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Fihri et al. (2007) reported many examples of using this catalyst 260 in Suzuki coupling to 
synthesize many natural products compounds.
154b 
For recycling the catalyst 260, a small 
amount of PEG-2000 (20% aqueous poly(ethyleneglycol) allows the recycling of the 
Pd(dppf)Cl2 catalyst for three times without any significant loss of catalytic activity.
154 
 
3.21.2. Conclusion 
The Suzuki coupling depends on the catalyst, the base, the solvent and temprature; As seen 
in Table 3.17, the solvents used were THF and DMF. Without adding water, the Suzuki 
reaction gave no coupled product 259 whereas when water was added to DMF (Equation 
3.26) the Suzuki reaction proceeded in good yield.   Moreover, the aqueous conditions 
increases the activity of the base, which will lead to accelerating the proceeding of 
coupling. In conclusion, it appears that the Suzuki coupling of 258 depends on the nature of 
the solvent; a more polar solvent leads to a better yields. With these conditions (5 mol% 
[Pd(dppf)Cl2].CH2Cl2,  Ba(OH)2, DMF, H2O, 45 ºC, 48h), we confirm the synthesize of 
triene 259. 
 
3.22. Deprotection of TBS-Group of t-butyldimethylsilyl ether 259 
Deprotection of t-butyldimethylsilyl ether 259 using silica supported sodium hydrogen 
sulfate (NaHSO4·SiO2) as a heterogeneous catalyst gave very poor yields of alcohol 262 
(10%) under different times and equivalents of the catalyst not like mentioned in the 
literature as an efficiency method.
155a
 However, the cleavage of the TBS-group of ether 259 
was conveniently carried out using 1 M tetrabutylammonium fluoride (TBAF) in THF 
which gave the corresponding allylic alcohol 262 (Equation 3.27) in an excellent 81% after 
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purification by silica gel chromatography.
155b 
Equation 3.27 Deprotection of t-butyldimethylsilyl ether 259 
 
  
Introducingly, compared to model compound 181, which underwent facile and rapid 
autooxidation in air (see Equation 3.15), compound 262 was found to be much more stable. 
This suggests that the benzene junction of 181  adds to the susceptibility to undergo 
autooxidation.  
 
3.23. Synthesis of ketone 263 
Trying to oxidize the allylic alcohol 262 using Dess–Martin periodinane146f (Equation 3.28) 
led to the allylic ketone 263 but all attempts to purify it on silica gel chromatography or 
activated alumina led to complete decomposition of the ketone 263. Hence it was used as a 
crude compound without any further purification in further experiments. However, 
compound 263 was isolated in clear (albeit crude) form in an estimated yield of 53%. 
Compound 263, according to 
1
H NMR,  was isolated as an 67:11:10 mixture of 
ZEE:ZEZ:ZEEE alkene isomers (Figure 3.19) and unidefined impurities. Moreover, by the 
comparision between 
1
H NMR spectra for both allylic protons (CH2) for ketones 215 and 
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263 as shown in Figures 3.19 and 3.20, there are similarities in the chemical shifts and the 
the J couplings (~ 6 Hz). 
 
Equation 3.28 Oxidation of allylic alcohol 262 
 
 
Figure 3.19 
1
H NMR of compound 263 as a crude sample. 
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Figure 3.20
1
H NMR of compound 215 
 
3.23.1. Another route for synthesis of ketone 263. 
The last oxidation step (Equation 3.28) led to a further adaption of the strategy to 
incorporate the ketone moiety required in synthon 137. To achieve this, a further 
modification was made to the synthesis route as proposed in Scheme 3.28.  
 
Scheme 3.28 Attempt of preparation of ketone 263 with Suzuki–Miyaura couplings 
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Hence, after desilylation of the O-TBS ether of 178 under mildly acidic methanolic 
conditions using DOWEX 50 WX8 200 mesh, the resulting secondary alcohol 264 was 
exposed to Dess–Martin periodinane146f oxidation to derive the ketone 265 in a gratifying 
yield of 86%. However, use of this ketone 265 for coupling with (Z)-alkenyl iodide 258 
under the previously employed mild Suzuki–Miyaura coupling conditions (Scheme 3.26) 
did not led to the desired product 263. The main problem was instability of the allylic triene 
ketone 265, which decomposed under the reaction conditions. 
 
Hence, attempts were made to protect ketone 265 as an enol ester to try and access either 
267 or 268, which could then be exposed to the Suzuki-Miyaura coupling conditions. 
Attempts to do an enol acetylation of ketone 265 with acetic anhydride in the presence of 
organic base at room temperature (Table 3.18) led to the decomposition of the compound 
265, and the compound 269 as one of the decomposition products especially isolated with 
entry 3 (Table 3.18). The boronate ester 269 has a crystalline structure (Figures 3.22 and 
3.23). 
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Equation 3.29 Attempts to enol acetylation of ketone 265 with acetic anhydride 
Table 3.18 Attempts to enol acetylation of ketone 265 with acetic anhydride 
Entry Conditions Result 
1 Et3N (1.05 eq), THF, rt, 48h. Traces 
2 Et3N (3 eq), DMAP (10 mol%), toluene, rt, 18h. Traces 
3 Pyridine (3 eq), rt, 3 days. Decomp. 269 (%) 
 
Figure 3.21 Structure of boronate ester 269 
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Figure 3.22 Molecular structure of Compound 269 (major conformation). Thermal 
ellipsoids are drawn at the 50% probability level. 
 
 
Figure 3.23 Disorder of the molecule 269 (H atoms are omitted) 
 
 
The origin of 269 as a by-product again suggests that facile autooxidation reactions are 
responsible for the decomposition of ketone 265. Therefore, either than using ketone 265 as 
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the key building block for the synthesis of viridenomycin, the precursor alcohol (262) and 
its TBS  ether (259) were used to developing the further methodologies required. 
 
3.24. Deprotection of N-Boc protecting group of 259 
The most common protecting group for amines is t-butyl carbamate (Boc) group, which is 
stable to hydrolysis under basic conditions and to many other nucleophilic agents. Selective 
cleavage of the N-Boc group of intermediate 259 was also examined in order to access the 
corresponding amine salt under acidic conditions (using TFA or HCl) for further 
elaboration via amide formation to the model of the lactam function in viridenomycin. 
However, since 259 contains both Boc and TBS protecting groups, it proved difficult to 
achieve deprotection without causing decomposition of compound 259 under a acidic 
conditions as follows: 1) TFA : DCM (50:50); 2) 4M HCl in dioxane. Simiarly, under basic 
conditions such as KO
t
Bu (8 eq), H2O,THF, reflux, 80 ºC, 23h decomposition also 
occured.
156
 The main reason for these problems stem from the sensitivity of TBS group and 
the triene structure under the acidic and basic conditions used.  
 
Equation 3.30 Attempts to cleavage of N-Boc of compound 259 under different conditions 
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Table 3.19 Attempts to cleavage of Boc under different conditions 
Entry Different conditions Result 
1 TFA : DCM (50:50) Decomposition 
2 4M HCl in dioxane Decomposition 
3 KO
t
Bu (8 eq), H2O,THF, reflux, 80 ºC, 23h Decomposition 
 
Hence, to achieve deprotection of the N-Boc group, another substrate, (Z)-alkenyl iodide 
258 is introduced instead of triene 259 and examined towards acidic deprotection 
conditions.  Fortunately, cleavage of N-Boc group was achieved clearly and efficiently 
using acidic conditions with the reagent TFA in DCM (50:50), which a quantitative yield of 
the TFA salt in 96% yield over 20 minutes (Scheme 3.29). The formation of 271 was 
confirmed by synthesis of the corresponding acetamide 272 in 94% yield using Ac2O/Et3N 
(Scheme 3.29). 
 
Scheme 3.29 Cleavage of Boc of compound 258 using TFA:DCM (50:50) 
 
 
TFA salt 271 was then subjected to Suzuki–Miyaura reaction conditions (Equation 3.31). 
Fortunately, the free amine 270 (without further purification) is appeared to be the major 
product by 
1
H NMR spectra.  
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Equation 3.31 Suzuki–Miyaura reaction 
 
 
 
The compound 273 was prepared in order to examine the purity of the secondry amine 270 
in the presence of  Et3N and  TFAA as shown in Equation 3.32. 
 
Equation 3.32 Intoducing N-trifluoroacetyl group on 273 
 
 
 
1,1'-Carbonyldiimidazole (CDI) 236 is used for activated 2-((1Z,3E)-4-iodobuta-1,3-
dienyl)benzoic acid 274, and then the secondary amine 270 was added. Unfotunatly, the 
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product, which isolated after SiO2 column chromatography purification, gave very broad 
signal by 
1
H NMR. Thus, it can not confirm the structure of the amide 275. 
 
Equation 3.33 The CDI-mediated amidation of secondry amine 270 with the carboxylic 
acid 274 
 
3.25. Introducing new mild cleavage protecting groups instead of Boc. 
Due to the issues encountered in deprotecting the N-Boc group in synthons such as 259, 
alternative N-protecting groups were examined that would be readily accessed from TFAA 
salt 271. In particular, two protecting groups (TFAA, phthalimide) were suggested for this 
purpose.  
 
3.25.1. N-Trifluoroacetyl protecting group  
The N-trifluoroacetyl group is easily removed by mild basic conditions and therefore, it is 
used as a protecting group for amines. In addition, triflouroacetic anhydride (TFAA) is used 
as a reagent for the cleavage N-Boc groups together with the introduction of a N-
trifluoroacetyl group, in situ. Therefore, iodoalkene 258 was exposed to TFAA to give the 
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(Z)-alkenyl iodide trifluoroacetamide 276 in 67% yield (Scheme 3.28).  
 
The gratifying in situ conversion of N-Boc system 258 was then followed by exposure to 
Suzuki–Miyaura coupling conditions with dienylboronate ester 175 to give the desired 
triene 273 in 65% yield. Hence, the triene 273 was isolated in 65% yield after silica gel 
chromatography. Since the trifluoroacetamide group of 273 would be cleavable under basic 
conditions, acidic methanolic conditions (DOWEX 50 WX8 200 mesh) were then applied 
for the deprotection of the TBS ether to derive the secondary alcohol 277, albeit in only 
31% yield (Scheme 3.30). However, the secondary alcohol isolated in pure form. 
 
Scheme 3.30 Protection of the secondary amino group with a trifluoroacetamide and 
synthesis of tricyclic core 277  
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3.25.2. N-Phthalimide protecting group  
The phthalimide amine-protecting group was selected as possible alternative to either the 
N-Boc or N-trifluoroacetamide protecting groups because the phthalimide group can be 
readily cleaved using hydrazine. The disadvantage of N-phthaloyl group could be easily  
that it is opened by other nucleophiles. Nonetheless, the phthalimide 279 was prepared 
from 271 by the dehydrative condensation of the amine salt  and phthalic anhydride 278 in 
the presence of triethylamine at 145 ˚C (Scheme 3.31) in a good yield (95%).  
 
Scheme 3.31 Protection of the secondary amino group with a phthalimide and synthesis of 
tricyclic core 280  
 
 
The resulting (Z)-alkenyl iodide 279 was then reacted with dialkenyl boronate ester 175 
under mild Suzuki–Miyaura couplings conditions (Scheme 3.31) to give the desired 
product 280 in low yield (37%). The easily opening of N-phthaloyl group could be the 
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reason of this low yield. 
 
3.26. Summary and Recommendations 
In summary, novel synthetic routes to synthesis southern polyene part 136 of 
viridenomycin 75 have been investigated. The enantioselective synthesis of the triene core 
259 has been achieved. A key aspect of this synthesis was the development of the 
iododeboronation (Equation 3.12) which, applied for the first time on this type of an 
alkenyl hindered boronate ester 171, gave the terminal (E)-alkenyl iodide 173, as one 
isomer (100%) and no sign of the (Z)-isomer 174. Therefore, this iododeboronation will be 
a very important method for practical use to prepare highly stereoselective terminal (E)-
alkenyl iodides. Many reactions were carried out efficiently including, Heck-Mizoroki 
couplings, Suzuki–Miyaura couplings and a simple and efficient method for the selective 
cleavage of tert-butoxycarbonyl (Boc) was introduced on the suitable substrate 258. In 
addition, two alternative protecting groups (TFAA, phthalimide) were studied. Further 
studies are necessary in order to complete the total synthesis of viridenomycin 75 by 
incorporating the southern polyene fragments prepared in this thesis. 
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CHAPTER IV 
Experimental Section 
 
4.1. General experimental  
All 
1
H NMR were recorded on either Varian Mercury-400, Bruker Avance-400 or Varian-
Mercury 500 spectrometers. 
13
C NMR spectra were recorded on Varian Mercury-400, 
Varian Mercury-500 and Bruker Avance-400 instruments at frequencies of 100 MHz. 
11
B 
NMR were recorded on the Bruker Avance-400 at a frequency of 128 MHz. Chemical 
shifts are expressed as parts per million downfield from the internal standard TMS except 
for 
11
B NMR which is expressed as parts per million downfield shift. IR spectra were 
recorded on a Perkin-Elmer Paragon 1000 FT-IR spectrometer. UV-Vis spectra were 
recorded on a Unicam UV2 spectrometer.  Column chromatography was performed on 
Davisil Silica gel, 60 meshes. TLC was performed on Polygram SIL G/UV254 plastic 
backed silica gel plates with visualization achieved using a UV lamp or staining with basic 
KMnO4. All glassware was oven dried (130 °C) before use and cooled under a positive 
pressure of argon. Dry solvents were dried by distillation from CaH2 (DCM, hydrocarbons) 
or sodium-benzophenone ketyl (THF).  The enantiomeric excesses were determined by 
HPLC using chiral column. All chemicals were purchased from standard chemical 
suppliers. Specific rotation is expressed in units: 10 degrees cm
2
 g
-1 
and the concentration 
(c) is expressed in units g dL
-1
. 
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4.2. Experimental Section. 
 
(±)-5-Trimethylsilyl-4-pentyn-2-ol 165 
 
 
n-BuLi (1.97 M in hexane, 7.3 mL, 14.2 mmol) is added dropwise to trimethylsilyacetylene 
164 (2.0 mL, 14.2 mmol) in dry ether (20 mL) at -78 °C.  After 30 mins of stirring, (±)-
propylene oxide (0.95 mL, 14.0 mmol) is added to the reaction solution and then BF3.Et2O 
(1.70 mL, 14.0 mmol) is added. After 2h of stirring at -75 °C, the reaction poured in a 
buffer solution (pH = 7.4 + Et2O + ice). After extraction, the combined organic layers are 
dried over MgSO4 and concentrated. Purification by silica gel chromatography (EtOAc : 
hexane, 2 : 8, as eluent) afforded 1.79 g (84%) of alcohol 165. All spectroscopic and 
analytical properties were identical to those reported in the literature.
139 
 
(±)-2-(tert-Butyldimethylsiloxy)-5-trimethylsilyl-4-pentyne 166 
 
 
 
TBSCl (2.89 g, 19.2 mmol, 2 eq) is added portionwise to trimethylsilyl alcohol 165 (1.50 g, 
6 mmol, 1 eq) in dry DCM (25 mL) at 0 °C under argon. The reaction is stirred at 0 °C for 
30 minutes, and then imidazole (0.82 g, 12.0 mmol, 1.25 eq) was added portionwise. The 
reaction mixture was stirred 19 hours, poured in a buffer solution (pH = 7.4 + Et2O + ice). 
The aqueous layer was extracted with ether (3 x 25 mL) and the combined organic layers 
  101 
were dried over MgSO4 and concentrated under reduced pressure. The resulting residue 
was purified via silica gel column chromatography (diethyl ether : hexane, 5 : 95, as eluent) 
to give the desired product 166 (2.10 g, 81%). All spectroscopic and analytical properties 
were identical to those reported in the literature.
157 
 
(±)-2-(tert-Butyldimethylsiloxy)-4-pentyne 167
 
 
 
 
To a solution of disilyl ether 166 (0.50 g, 1.9 mmol) in 4:1 MeOH-Et2O (20 mL) under 
argon is added K2CO3 (0.281 g, 2.0 mmol) which finely powdered (dried under 0.5 mmHg 
with the gun with hot air during 1h). After 48h the reaction mixture is partitioned between 
ether and water and the aqueous layer was extracted with Et2O (2 x 25 mL). The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The residue was purified 
by silica gel column chromatography (diethyl ether : petroleum ether, 10 : 90, as eluent) to 
give 0.32 g  (89%) of TBS ether 167 as a colourless oil, Rf  0.83 (hexane : EtOAc, 4:1); 
1
H 
NMR (400 MHz, CDCl3, 20 °C): 0.07 (s, 3H, SiMe), 0.08 (s, 3H, SiMe), 0.89 (9H, s, 
t
BuSi), 1.23 (3H, d, J  6.0, CHMe), 1.97 (1H, t, J 2.7, CCH), 2.24 (1H, ddd, J 16.5, 7.1, 
2.7, CHH), 2.35 (1H, ddd, J  16.5, 5.6, 2.7, CHH)  3.92-3.99 (1H, dp, J 7.1, 6.0, CHOTBS 
); 
13
C NMR (101 MHz, CDCl3): c –4.7 (SiMe), –4.6 (SiMe), 18.1 (SiCMe3), 23.2 (MeCH), 
25.8 (Me3C), 29.3 (CH2), 67.5 (CCH), 69.6 (CCH), 81.9 (HCOTBS); Spectroscopic and 
analytical properties were identical to those reported in the literature.
141 
 
  102 
(±)-2-(tert-Butyldimethylsiloxy)-4-pentyne 167
 
 
 
 
(±)-Pent-4-yn-2-ol 168 (1.0 g, 11.9 mmol) was dissolved in a solution of DCM (10 mL), 
CH3CN (10 mL), and TBSCl (1.810 g, 12.0 mmol, 1.01 eq), imidazole (1.21 g, 17.8 mmol, 
1.5 eq) and DMAP (0.15 g, 1.2 mmol, 10 mol%) was then added portionwise and left to stir 
for 3 days. The reaction was diluted with DCM (50 mL), washed with brine (30 mL), water 
(30 mL) and dried (MgSO4). The organic layer was evaporated, which afforded an oil that 
was purified by silica gel column chromatography (diethyl ether : petroleum ether, 20 : 80, 
as eluent) to yield 167 (1.533 g, 65%) as a colorless oil, spectral data mentioned above.  
 
(±) trans-2-[4-(tert-Butyldimethylsiloxy)-1-pentenyl]-4,4,6-trimethyl-1,3,2-
dioxaborolane 171
  
To a stirred terminal alkyne 167 (5.00 g, 25.20 mmol) at 0 °C under argon, catecholborane 
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(3.00 g, 25.20 mmol) was added dropwise. After that, the reaction mixture heated to 65 °C. 
After the mixture is stirred until the consumption of starting material by NMR and detected 
the formation of a mixture of the product 170 : 169 (9:1) as pale yellow oil; which have the 
following spectral data:  
1
H NMR (400 MHz, CDCl3, 20 °C): δH 0.14 (6H, s, Me2Si), 0.97 
(9H, s, Me3CSi), 1.25 (3H, d, J 6.1 Hz, MeCHOSi), 2.38 - 2.47 (2H, m, CH2), 4.03 (1H, q, 
J 6.1 Hz, CHOSi), 5.82 (1H, dt, J, 18.0, 1.4 Hz,  =CHB), 7.02 – 7.06 (1H, m, -CH=), 7.10-
7.12 (2H, m, H-3
/
 & H-4
/
), 7.25-7.27 (2H, m, H-2
/
 & H-5
/
); 
13
C NMR (100 MHz, CDCl3) 
δC (100 MHz, CDCl3) -4.7 (MeSi), -4.5 (MeSi), 18.1 (Me3CSi), 23.6 (MeCHOSi), 25.8 
(Me3CSi), 46.5 (CH2), 67.9 (CHOSi), 112.2 (C-3
/
 & C-4
/
), 121.2 (=CHB), 122.4 (C-2
/
 & C-
5
/
), 148.3 (C-1
/
 & C-6
/
), 154.3 (CH2CH=); Compound 169: 
1
H NMR (400 MHz, CDCl3, 20 
°C): δH 0.14 (6H, s, Me2Si), 0.97 (9H, s, Me3CSi), 1.30 (3H, d, J 6.1 Hz, MeCHOSi), 2.38 - 
2.47 (2H, m, CH2), 4.14 (1H, q, J 6 Hz, CHOSi), 5.97 (1H, d, J, 3.3 Hz,  =CHH), 6.32 (1H, 
d, 3.2 Hz, -CHH=), 7.15-7.18 (2H, m, H-3
/
 & H-4
/
), 7.25-7.27 (2H, dd, J, 6, 3 Hz,  H-2
/
 & 
H-5
/
) 
After that (18 hours) the product was cooled to room temperature, and diluted with DCM 
(50 mL) allowing the addition of 2-methylpentane-2,4-diol (2.98 g, 25.2 mmol) and  sat. 
aq. NaHCO3 (40 mL). After stirring for 2 hours, the reaction is diluted with DCM (50 mL). 
The organic layer was washed with 1M NaOH (3 x 50 mL) followed by NaHCO3 (50 mL) 
and water (50 mL). The organic layer was dried (MgSO4) and concentrated to give a yellow 
crude, which was purified by silica gel column chromatography (EtOAc : petroleum ether, 
5 : 95, as eluent) to afford 7.50 g (91%)  as a mixture of of the product 171 : 172 (8:1) as 
pale yellow oil; Rf 0.76 (hexane : EtOAc, 4:1); λmax /cm
-1
 (film) 2970 (w, =C-H), 1461 (s, 
  104 
C=C), 1451 (s), 1255 (s); 
1
H NMR (400 MHz, CDCl3, 20 °C): δH 0.04 (s, 6H, Si(Me3)2), 
0.88 (s, 9H, 
t
BuSi), 1.14 (d, J = 6.1 Hz, 3H, CHMe3), 1.25 (d, J = 6.1 Hz, 3H, 
BOCCHMe3), 1.28 (6H, s, BOCMe2), 1.76 (1H, d, J 11.6, 2.2 Hz, BOCCHCHH), 1.79 (1H, 
dd, J  10.8,  3.0 Hz, BOCCHCHH), 2.15-2.34 (2H, m, CH2CH=CH), 3.82-3.88 (1H, m, 
CHOBO), 4.15-4.24 (1H, m, CHOTBS ), 5.37 (1H, d, J 17.7 Hz, CH=CHB), 6.50 (1H, dq, 
J = 17.7, 6.8 Hz, CH2CH=CHB); 
13
C NMR (101 MHz, CDCl3): δc –5.6 (SiMe2), 18.1 
(SiC(Me)3), 23.2 (MeCHOTBS), (MeCHOB), 23.7 (MeCHOB), 25.7 (SiCMe3), 28.9 
(MeCOB), 29.4 (boronate CH2), 30.2 (MeCOB), 46.1 (CH2CH=), 64.4 (CHOTBS), 67.6 
(BOCMe2), 147.8 (CH2CH=); δB (128 MHz, CDCl3) 25.64; LRMS (ES
+
): m/z (rel. int.) 350 
(MHNa
+
, 27%), 349.4 (MNa
+
, 72%), 295.3 (MNa
+
-H-Me2, 29%), 277.3 (MNa
+
-t-Bu-Me, 
32%), 235.2 (MHNa
+
-TBS, 14%), 195.2 (M
+
-OTBS, 15%), 141.2 (100%); HRMS (TOF 
ES
+
): Acc. MS calc. for C17H34
10
BO3NaSi
+
 [M-H+Na]
+
, 348.2383; found 348.2396; 
together with the compound 172: 
1
H NMR (400 MHz, CDCl3, 20 °C): δH 0.04 (s, 6H, 
Si(Me3)2), 0.88 (s, 9H, 
t
BuSi), 1.14 (d, J = 6.1 Hz, 3H, CHMe3), 1.25 (d, J = 6.1 Hz, 3H, 
BOCCHMe3), 1.28 (6H, s, BOCMe2), 1.76 (1H, d, J 11.6, 2.2 Hz, BOCCHCHH), 1.79 (1H, 
dd, J  10.8,  3.0 Hz, BOCCHCHH), 2.15-2.34 (2H, m, CH2CH=CH), 3.91-3.97 (1H, m, 
CHOTBS), 4.15-4.24 (1H, m, CHOBO), 5.50 (1H, d, J 4 Hz, CH=CHB), 5.76 (1H, d, J 4 
Hz, CH2CH=CHB). 
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 (±)-(E)-4-(t-Butyldimethylsilyloxy)-1-iodopent-1-ene 173 
 
 
 
To a solution of (±)-(E)-2-[4-(tert-butyldimethylsiloxy)-1-pentenyl]-4,4,6-trimethyl-1,3,2-
dioxaborolane 171 (1.00 g, 3.06 mmol) in THF (10 mL) under Ar at room temperature, was 
added sodium hydroxide (1.84 mL, 9.19 mmol, 5 M in de-ionized water). The reaction 
mixture left to stir at room temperature for 10 minutes then a solution of iodine (1.55 g, 
6.13 mmol) dissolved in THF (5 mL) was added dropwise over ca. 1 minute. The reaction 
mixture was left to stir at room temperature for 4 h in the absence of light, followed by the 
quenching with 5% aqueous sodium metabisulfite solution (40 mL). The aqueous layer was 
extracted with diethyl ether (3 x 25 mL), the combined organic extracts were washed with 
5% aqueous sodium metabisulfite solution (40 mL), water (40 mL), brine (40 mL), dried 
(MgSO4), filtered and concentrated. The crude product was purified by silica gel 
chromatography (petroleum ether as eluent), to give (±)-(E)-4-(tert-butyldimethylsilyloxy)-
1-iodopent-1-ene 173 (0.714 g, 71%) as a light sensitive yellow oil (E-isomeric purity > 
99%); Rf  0.83 (hexane : EtOAc, 4:1);  λmax /cm
-1
 (film): 2928 (w, =C-H), 1472 (w, C=C), 
834 (vs), 773 (vs); 
1
H NMR  (400 MHz, CDCl3, 20 °C): δH 0.05 (6H, s, MeSi), 0.88 (9H, s, 
Me3CSi), 1.12 (3H, d, J 6.0 Hz, MeCHOSi), 2.13- 2.22 (2H, m, CH2), 3.84 (1H, h, J 6.1 Hz, 
CHOSi), 6.02 (1H, dt, J 14.4,  1.3 Hz, -CH=), 6.51 (1H, dt, J, 14.4, 7.6 Hz,  =CHI); 
13
C 
NMR (101 MHz, CDCl3): δc -4.8 (MeSi), -4.5 (MeSi), 18.1 (Me3CSi), 23.5 (MeCHOSi), 
25.84 (Me3CSi), 46.0 (CH2), 67.5 (CHOSi), 128.4 (=CH), 143.6 (=CH); LRMS (ES
+
): m/z 
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(rel. int.) 269.3 (M-
t
Bu, 100%); LRMS (EI): m/z (rel. int.) 324.9 (M-H, 21%), 310.9 (M-I, 
100%); HRMS (TOF ES
+
): Acc. MS calc. for C11H22OSiI
+
 [M-H]
+
, 325.0485; found 
325.0476. 
 
 
(±)-(Z,E)-4-(t-Butyldimethylsilyloxy)-1-iodopent-1-ene, 173 
 
 
 To a stirred solution of boronate 171 (3.251 g, 10.0 mmol) in dry THF (20 mL) under 
argon at -78 ºC in the absence of light, was added dropwise NaOMe (23.9 mL of a 0.5 M 
solution in MeOH, 12.0 mmol). The reaction mixture is stirred at rt for 30 min. After this 
time, the reaction mixture is cooled to -78 ºC and ICl (23.9 mL of a 1.0 M solution in 
DCM, 12.0 mmol) was added over 5 min. The reaction is stirred for 30 min. and then, the 
reaction was allowed to warm to room temperature. After 2 h, the reaction was diluted with 
Et2O (50 mL) before washing with 5% aq. Na2S2O5 (20 mL, 2x), water (25 mL) and brine 
(25 mL) before drying (MgSO4) and solvent removal to afford the crude product which 
purified by silica gel chromatography (petroleum ether,  as eluent) provided the compound 
173 (2.025 g, 62%) as a light sensitive yellow oil (3:1 E:Z mixture of isomers which could 
not be separated), which was identical to that reported previously; together with the 
compound 174: 
1
H NMR (400 MHz, CDCl3, 20 °C):H  0.04 (6H, s, Me2Si), 0.88 (9H, s, 
Me3CSi), 1.15 (3H, d, J 6.1, MeCHOSi), 2.34-2.37 (2H, m, CH2), 3.91 (1H, p, 6, CHOSi), 
5.84 (1H, q, J 7.1, -CHI), 6.08 (1H, dt, J, 7.1, 1.5,  =CH). 
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(±) 2-(2E, 3E)-[6-(tert-Butyldimethylsiloxy)-1,3-heptadienyl]-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane
 
175
 
 
To a dried Schlenk tube under a positive pressure of argon was added Pd(OAc)2 (120 mg, 
0.53 mmol), silver(I) acetate (1.92 g, 11.8 mmol), tri(o-tolyl)phosphine (325 mg, 1.0 
mmol), and dry MeCN (25 mL). The mixture degassed using the freeze-pump-thaw method 
(2 x), and vinylboronate pinacol ester 174 (1.97 g, 12.3 mmol) and (E)-alkenyl iodide 173 
(3.49 g, 10.7 mmol) were added, and then the mixture was degassed using the freeze-pump-
thaw method (2 x) and heated to 50 °C with vigorous stirring. After 48 h, the mixture was 
cooled, diluted with Et2O (50 mL), passed through Celite, washed with 5% HCl (20 mL), 
water (20 mL), and brine (20 mL), dried (MgSO4), and evaporated to give crude product as 
a yellow oil. Purification by SiO2 chromatography (EtOAc : petroleum ether,  1:19, as 
eluent) gave the desired product 175 as pale yellow oil (33.4 g, 91%); Rf
 
 0.64 (hexane: 
EtOAc, 4:1); UV λmax
EtOH
 nm (log ε) 203 (4.032), 244 (4.206), 276 (3.677); λmax /cm
-1
 
(film) 2927 (w, C-H), 1604 (s, C=C), 1359 (s), 1255 (s), 1144 (s), 1005 (vs), 833 (vs), 772 
(vs);  
1
H NMR (400 MHz, CDCl3) δH 0.03 (3H, s, MeSi), 0.04 (3H, s, MeSi), 0.87 (9H, s, 
Me3CSi), 1.11 (3H, d, J 6.1 Hz, MeCHOSi), 1.27 (12H, s, Me2CCMe2), 2.22 (2H, m, CH2), 
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3.84 (1H, q, J  6.0 Hz, CHOSi), 5.43 (1H, d, J 17.7 Hz, =CHB), 5.88 (1H, dt, 15.3, 7.5 Hz, 
=CHCH2), 6.14 (1H, ddd, J 15.3, 10.4, 0.8 Hz, CH=CH-CH=), 6.98 (1H, dd, J 17.7, 10.4 
Hz, -CH=CHB);  
13
C NMR (100 MHz, CDCl3) δC -4.7 (MeSi), -4.5 (MeSi), 18.1 (Me3CSi), 
23.5 (MeCHOSi), 24.8 (Me3CSi), 25.8 (Me2CCMe2), 43.1 (CH2), 68.3 (CHOSi), 83.1 
(COB), 134.4 (=CH), 135.8 (=CH), 150.1 (CH=CHB); δB (128 MHz, CDCl3) 30.56; LRMS 
(TOF AP
+
): m/z (rel. int.) 337.1 (M-Me, 70%), 221.2 (M-OTBS, 100%); HRMS (TOF 
AP
+
): Acc. MS calc. for C19H38
10
BO3
28
Si
+ 
[M+H]
+
, 352.2720; found 352.2714. Further, 
purification by SiO2 chromatography (EtOAc : petroleum ether,  1:19, as eluent) gave also 
the Suzuki–Miyaura product tert-butyl-dimethyl-(1-methyl-hexa-3,5-dienyloxy)-silane 176 
as pale yellow oil (200 mg, 8%); Rf  0.78 (hexane : EtOAc, 4 : 1); UV λmax
EtOH
 nm (log ε) 
196 (3.072), 224 (3.656), 252 (3.015), 272 (2.790); λmax /cm
-1
 (film) 2957 (w, C-H), 1500 
(s, C=C), 1387 (s), 1301 (s), 1183 (s), 1004 (vs), 830 (vs), 771 (vs); 
1
H NMR (400 MHz, 
CDCl3, 20°C) δH: 0.03 (3H, s, MeSi), 0.04 (3H, s, MeSi), 0.88 (9H, s, Me3CSi), 1.12 (3H, d, 
J 6.1 Hz, MeCHOSi), 2.13-2.26 (2H, m, CH2CH=), 3.83 (1H, q, J 6.0 Hz, CHOTBS), 4.97 
(1H, dt, J 10.2, 1.7 Hz, =CHH), 5.10 (1H, dt, J 16.9, 1.7 Hz, =CHH), 5.68 (1H, dt, J 15.2, 
7.5 Hz, CH2CH=), 6.05 (1H, dd, J 15.2, 10.2 Hz,  CH=CH=CHH); 6.31 (1H, dt, J 16.9, 
10.2 Hz,  CH=CH=CHH); 
13
C NMR (101 MHz, CDCl3) δc: -4.7 (MeSi), -4.5 (MeSi), 18.1 
(Me3CSi), 23.6 (MeCHOSi), 25.9 (Me3CSi), 43.0 (CH2), 68.5 (CHOTBS), 115.1 (=CH2), 
131.8 (=CH), 132.9 (=CH), 137.2 (CH2CH=); LRMS (EI): m/z (rel. int.) 211.2 (M-Me, 
2%), 169.2 (M-
t
Bu, 60%), 159.2 (MeCHOTBS-M, 100%). 
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tert-Butyldimethyl((4E,6E)-7-(4,4,6-trimethyl-1,3,2-dioxaborinan-2-yl)hepta-4,6-dien-
2-yloxy)silane 178 
 
To a dried Schlenk tube under a positive pressure of argon was added silver(I) acetate (0.70 
g, 4.17 mmol),  Pd(OAc)2 (0.043 g, 0.193 mmol), tri(o-tolyl)phosphine (0.12 g,  0.39 
mmol), and dry MeCN (20 mL). The mixture degassed using the freeze-pump-thaw method 
(3 x), and vinylboronate ester 177 (0.66 g, 4.25 mmol) and alkenyl iodide 173 (1.26 g, 3.86 
mmol) were added, and then the mixture was degassed using the freeze-pump-thaw method 
(2 x) and heated to 50 °C with vigorous stirring. After 48h, the mixture was cooled, diluted 
with Et2O (50 mL), passed through Celite, washed with 5% HCl (25 mL), water (40 mL), 
and brine (40 mL), dried (MgSO4), and evaporated to give crude product as a yellow oil. 
Purification by SiO2 chromatography (EtOAc : petroleum ether, 1 : 19, as eluent) gave the 
desired product 178 as pale yellow oil (1.24 g, 93%); Rf  0.69 (hexane : EtOAc, 4 :1 ); UV 
λmax
EtOH
 nm (log ε) 244 (4.324), 278 (3.791); λmax /cm
-1
 (film) 2928 (w, C-H), 1500 (w, 
C=C), 1387 (s), 1301 (s), 1183 (s), 1003 (vs), 831 (vs), 771 (vs); 
1
H NMR (400 MHz, 
CDCl3, 20°C): δH 0.04 (6H, s, MeSi), 0.88 (9H, s, Me3CSi), 1.11 (3H, d, J 6.1, MeCHOSi), 
1.27 (3H, d, J 6.2, BOCHMe), 1.30 (6H, d, J 1.7 Hz, BOCMe2), 1.50 (1H, dd, J 13.9, 11.8 
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Hz, BOCCHCHH), 1.78 (1H, dd, J 13.9, 2.9 Hz, BOCCHCHH), 2.13-2.30 (2H, m, 
CH2CH=CH), 3.83 (1H, q, J 6.1 Hz, CHOTBS), 4.17-4.26 (1H, m, CHOB), 5.38 (1H, d, J 
17.5 Hz, CH=CHB), 5.82 (1H, dt, J 15.2, 7.5 Hz, CH2CH=), 6.11 (1H, ddd, J 15.2, 10.4, 
0.8 Hz,  CH=CH=CHB); 6.89 (1H, dd, J 17.4, 10.2 Hz, CH=CH=CHB); 
13
C NMR (101 
MHz, CDCl3): δc -4.7 (MeSi), -4.6 (MeSi), 18.1 (Me3CSi), 23.1 (MeCHOB), 23.4 
(MeCHOSi), 25.9 (Me3CSi), 28.1 (MeCOB), 31.3 (MeCOB), 43.1 (CH2CHOTBS), 46.0 
(boronate CH2), 64.7 (CHOTBS), 68.4 (BOCMe2),  70.6 (MeCHOB), 133.7 (=CH), 134.0 
(=CH), 134.7 (=CH), 146.5 (CH2CH=); δB (128 MHz, CDCl3) 25.85; LRMS (TOF AP
+
): 
m/z  (rel. int.) 337.1 (M-Me, 22%), 315.2 (100%), 221.2 (M
+
-OTBS, 100%), 165 (62%); 
HRMS (TOF AP
+
): Acc. MS calc. for C19H38
10
BO3
28
Si
+ 
[M+H]
+
, 352.2720; found 
352.2717. The compound 176 was isolated by SiO2 chromatography (EtOAc : petroleum 
ether, 1 : 19, as eluent) as pale yellow oil (52 mg, 6%); which showed identical 
spectroscopic properties to those previously reported. 
 
 tert-Butyldimethyl((4E,6E)-7-phenylhepta-4,6-dien-2-yloxy)silane 
 
179 
 
 
 
To a dried Schlenk tube under a positive pressure of argon was added iodobenzene 180 
(400 mg, 1.96 mmol) and dialkenyl boronate 175 (698 mg, 1.98 mmol) in DMF (20 mL) 
and H2O (2 mL). The mixture was degassed using the freeze-pump-thaw method (3 x), and 
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Ba(OH)2 ( 403 mg, 2.53 mmol) and Pd(dppf)Cl2 (72 mg, 0.10 mmol) were added, and then 
the mixture was degassed using the freeze-pump-thaw method (3 x ). The mixture was 
vigorously stirred at room temperature for 48h before it was diluted with EtOAc (50 mL) 
and passed through Celite, washed with 5% HCl (25 mL), water (25 mL), and brine (25 
mL), dried (MgSO4), and evaporated to give crude product as yellow oil. Purification by 
SiO2 chromatography (EtOAc : petroleum ether, 5 : 95, as eluent) gave the desired product 
179 as yellow oil (396 mg, 71%); Rf 0.78 (hexane : EtOAc, 4:1); UV λmax
EtOH
 nm (log ε) 
204 (3.680), 228 (3.621), 272 (3.779), 284 (3.737), 300 (3.627), 316 (3.443), 348 (2.886); 
max /cm
-1
 (film) 2955 (m), 2927 (m), 2855 (m), 1360 (s), 1252 (s), 1080 (s), 987 (vs), 833 
(vs), 723 (vs), 690 (s); 
1
H NMR (400 MHz, CDCl3, 20 °C): δH 0.05 (3H, s, MeSi ), 0.06 
(3H, s, MeSi ), 0.89 (9H, s, Me3CSi), 1.12 (3H, d, J 6.1, MeCHOSi), 2.20-2.31 (2H, m, 
CH2CHOSi), 3.83-3.91 (1H, m, CHOSi), 5.77-5.84 (1H, dt, J 15.1, 7.5, =CHCH2), 6.21 
(1H, dd, J 15.2, 9.8, CH=CHCH2), 6.45 (1H, d, J 15.7, PhCH=CH), 6.75 (1H, dd, J 15.7, 
10.2, PhCH=CH), 7.17-7.22 (1H, m, H-4),  7.28-7.32 (2H, m, H-3  & H-5),  7.37-7.39 
(2H, m, H-2  & H-6 ); 13C NMR (101 MHz, CDCl3): δc -4.6 (MeSi), -4.5 (MeSi), 18.1 
(Me3CSi), 23.6 (MeCHOSi), 25.8 (Me3CSi), 43.2 (CH2), 68.6 (CHOSi), 126.2 (C-2  & C-
6), 127.1 (PhCH=CH), 128.5 (C-3  & C-5 ), 129.3 (CH=CHCH2),130.4 (PhCH=), 132.1 
(=CHCH2), 137.0 (C-1); LRMS (CI): m/z (rel. int.) 287.1 (M-Me, 2%), 248 (M-
t
Bu, 8%), 
171.1 (M-OTBS, 40%), 159.1 (MeCHOTBS-M, 100%). 
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(4E,6E)-7-Phenylhepta-4,6-dien-2-ol 181 
 
The TBSO-ether compound 179 (390 mg, 1.29 mmol) was dissolved in THF (15 mL) and 
TBAF (2.6 mL, 2.58 mmol, 1M solution in THF) was added drop wise at rt. The result 
mixture is stirred at rt until the TLC indicated the consumption of starting material.  The 
reaction mixture is diluted with 50 mL EtOAc, washed with 25 mL brine, 25 mL water, 
dried over MgSO4, concentrated in vacuo and the residue was purified by SiO2 
chromatography (EtOAc : petroleum ether, 1:4 as eluent) to give the desired product 181 as 
yellow solid (180 mg, 74%); Rf  0.18 (hexane: EtOAc, 4:1); Mp 48-50 C; UV λmax
EtOH
 nm 
(log ε) 192 (3.624), 200 (3.563), 228 (3.463), 288 (3.492), 332 (3.563); max /cm
-1
 (film) 
3294 (br, OH), 3019 (m), 2963 (m), 2926 (m), 1595 (m), 1447 (m), 1370 (m), 1119 (m), 
1066 (s), 992 (vs), 746 (vs), 690 (vs); 
1
H NMR (400 MHz, CDCl3, 20 °C): δH 1.24 (3H, d, J 
6.2, MeCHOH), 2.23-2.38 (2H, m, CH2CHOH), 3.85-3.93 (1H, m, CHOH), 5.82 (1H, dt, J 
15.1, 7.6, =CHCH2), 6.30 (1H, ddd, J 15.1, 10.4, 0.6, CH=CHCH2), 6.49 (1H, d, J 15.7, 
PhCH=CH), 6.77 (1H, dd, J 15.7, 10.4, PhCH=CH), 7.17-7.23 (1H, m, H-4),  7.28-7.32 
(2H, m, H-3  & H-5),  7.37-7.39 (2H, m, H-2  & H-6 ); 13C NMR (101 MHz, CDCl3): δc 
22.9 (MeCHOH), 42.8 (CH2), 67.4 (CHOH), 126.2 (C-2  & C-6), 127.4 (PhCH=CH), 
128.6 (C-3  & C-5 ), 128.8 (CH=CHCH2),130.6 (PhCH=), 131.3 (=CHCH2), 133.8 (C-1); 
LRMS (CI): m/z (rel. int.) 188.2 (M
+
, 30%), 171.1 (M-OH, 90%), 129.0 (100%), 91% 
(PhCH2-M, 56%); HRMS (TOF AP
+
): Acc. MS calc. for calcd for C13H15O
+
 [M-H]
+
, 
187.1123; found 187.1112. 
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(4E,6E)-7-Phenylhepta-4,6-dien-2-one
 
215 
 
 
To a solution of 181 (120 mg, 0.64 mmol) in DCM (6 mL) under Ar at 0 C was added 
NaHCO3 (214 mg, 2.55 mmol), Dess-Martin periodinane (405 mg, 0.96 mmol) and tert-
butanol (0.05 mL, 0.51 mmol) The resulting mixture was stirred for 4 h at 0 ºC before a 
saturated aqueous Na2S2O3 solution (5 mL)  was added. After being stirred for 10 min, the 
mixture was extracted with ether (20 mL x 3). The combined organic layers were washed 
with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was 
dissolved in DCM, passed through silica-gel, and evaporated to provide the allylic ketone 
215 as a mixture of E/Z and enol 66:10:1 (120 mg, 100%): Rf  0.31 (hexane: EtOAc, 4:1); 
UV λmax
EtOH
 nm (log ε) 208 (3.516), 268 (3.299), 280 (3.298), 328 (2.729); max /cm
-1
 (film) 
2358 (m, =C-H),1715 (s, C=O), 1494 and 1447 (m, C=C aromatic), 1356 (m), 1236 (s), 989 
(s), 742 (s), 691(vs); 
1
HNMR (400 MHz, CDCl3): H 2.19 (3H, s, MeCO), 3.27 (2H, d, J  
7.3, CH2), 5.89 (1H, dt, J  15.2, 7.3, =CHCH2), 6.20- 6.30 (1H, m, CH=CHCH2), 6.50 (1H, 
d, J 15.7, PhCH=CH), 6.77 (1H, dd, J 15.7, 10.4, PhCH=CH), 7.19-7.32 (1H, m, H-4),  
7.29-7.32 (2H, m, H-3  & H-5),  7.37-7.39 (2H, m, H-2  & H-6 ); C (101 MHz, CDCl3) 
29.4 (MeCO), 47.5 (CH2), 125.7 (C-2  & C-6), 126.3 (C-3  & C-5 ), 127.5 (PhCH=CH), 
128.3 (CH=CHCH2),128.5 (PhCH=), 132.27 (=CHCH2), 137.1 (C-1); 206.4 (C=O); LRMS 
(AP
+
): m/z (rel. int.) 188.1 (M
+
, 15%), 187.1 (M+H, 100%), 170.1 (M-O, 15%), 169.1 (M-
OH, 82%); HRMS (TOF AP
+
): Acc. MS calc. for calcd for C13H15O
+
 [M+H]
+
, 187.1123; 
  114 
found 187.1120. 
 
For Z-isomer of ketone 215, 
1
H NMR (400 MHz, CDCl3): H  2.21 (3H, s, MeCO), 3.27 
(2H, dd, J  7.6 & 1.2, CH2), 5.65-5.72 (1H, m, =CHCH2), 6.33- 6.44 (1H, m, CH=CHCH2), 
6.61 (1H, d, J 15.2, PhCH=CH), 6.95 (1H, ddd, J 15.4, 11.1 & 1.1, PhCH=CH), 7.19-7.24 
(1H, m, H-4),  7.29-7.32 (2H, m, H-3  & H-5),  7.37-7.39 (2H, m, H-2  & H-6 ). 
 
 
 (4E,6E)-7-Phenylhepta-4,6-dien-2-one
 
215 
 
 
To a solution of allylic alcohol 181 (100 mg, 0.53 mmol) in dry DCM (4 mL) under a 
positive pressure of argon at 0 C were added NaHCO3 (134 mg, 1.59 mmol, 3 eq) and 
Dess-Martin periodinane (450 mg, 1.06 mmol, 2 eq). The resulting mixture was stirred for 
2.5 h at 0 ºC, then solution of a saturated Na2S2O3 (10 mL)  was added. After stiring for 10 
min, two layers were separted. The aqueous layer was extracted with ether (25 mL x 2). 
The combined organic layers were washed with brine (30 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was dissolved in DCM passed through silica-gel, and 
evaporated to provide the allylic ketone 215 as a mixture of E:Z 7:1 (90 mg, 91%), which 
was identical to that previously reported. 
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Attempt to synthesis (4E,6E)-7-Phenylhepta-4,6-dien-2-one
 
215 by Swern oxidation 
 
 
To a stirred solution of oxalyl chloride (0.12 mL, 1.36 mmol, 2 eq) in CH2Cl2 (2 mL) at –
78 °C under argon was added dropwise DMSO (0.19 mL, 2.72 mmol, 4 eq) over 1 min.  
Following stirring for 10 min, a solution of allylic alcohol 181 (128 mg, 0.68 mmol) in 
CH2Cl2 (2 mL) was added dropwise over 1 min.  After stirring for 15 min, triethyl amine 
(0.47 mL, 3.40 mmol, 5 eq) was added dropwise over 2 min, then following stirring for 5 
min, then the reaction mixture left to warm to with stirring for 1h. The consumption of 
starting was detected by TLC.  The reaction was poured in H2O (50 mL), the aqueous layer 
was extracted with CH2Cl2 (2 × 25 mL), then the combined organic layers were dried 
(MgSO4) and evaporated. Purification of the residue by flash SiO2 column chromatography 
(EtOAc: petroleum ether, 1:9 as eluent) gave the allylic ketone 215 (50 mg, 39%), which 
was identical to that previously reported. 
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(2Z,4E,6E)-7-Phenylhepta-2,4,6-trien-2-yl acetate 216 
 
 
To a solution of substrate 215 (25 mg, 0.13 mmol), in DCM (5 mL) under Ar at room 
temperature, was added pyridine (0.02 mL, 0.27 mmol) and Ac2O (0.01 mL, 0.13 mmol). 
The reaction mixture left to stir at rt for 24 h and the solvent removed. The crude product 
was subjected to silica gel column chromatography (petroleum ether : EtOAc, 8 : 1, as 
eluent) to give the desired product 216 as a yellow thick oil (21 mg, 68%) as a mixture of  
E and Z enol esters (EEZ : EEE = 5 : 1): Rf 0.38 (hexane : EtOAc, 4 : 1); UV λmax
EtOH
 nm 
(log ε) 200 (3.569), 308 (3.495), 316 (3.480), 336 (3.351);  max /cm
-1
 (film) 2926 (m, =C-
H), 1746 (s, C=O), 1666, 1493 and 1448 (m, C=C), 1371 (s), 1204 (vs), 989 (vs), 747 (vs), 
689 (vs); 
1
H NMR (400 MHz, CDCl3): H 2.01 (3H, s, MeCH=), 2.23 (3H, s, MeCO), 5.74 - 
5.77 (1H, m, =CHCO2Me), 6.31 - 6.33 (2H, m, H-4 & H-5), 6.54 (1H, d, J 15.5, 
PhCH=CH), 6.78 - 6.84 (1H, m, PhCH=CH), 7.18 - 7.23 (1H, m, H-4),  7.28 - 7.32 (2H, 
m, H-3  & H-5),  7.37 - 7.39 (2H, m, H-2  & H-6 ); 13C NMR (101 MHz, CDCl3): δc 19.9 
(C-1), 20.8 (MeCO), 117.5 (C-3), 125.6 (C-6), 126.3 (C-2  & C-6), 127.4 (C-4), 128.5 (C-
3  & C-5 ), 132.2 (PhCH=), 132.6 (C-4  & C-5), 137.3 (C-1), 146.6 (=C-O), 168.6 (C=O); 
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LRMS (TOF AP
+
): m/z (rel. int.) 229 (M+H, 30%), 185 (M-Ac, 40%), 169 (M-AcO, 
100%);  HRMS (TOF AP
+
): Acc. MS calc. for C15H17O2
+
 [M+H]
+
, 229.1229; found 
229.1224. 
 
(4E,6E)-7-Phenylhepta-1,4,6-trien-2-yl acetate 217 
Compound 217 was also isolated as a yellow thick oil (11 mg, 38%) as a mixture of  E and 
Z enol esters (1E, 4E, 6E : 1Z, 4E, 6E = 4:1); 
1
H NMR (400 MHz, CDCl3, 20 °C): δH 2.04 
(s, 3, Me), 2.31 – 2.45 (m, 2H, CH2), 4.98 (dd, J = 12.5, 6.3 Hz, 2H, C=CH2), 5.85 – 5.64 
(m, 1H, =CHCH2), 6.47 (1H, d, J = 15.6 Hz, PhCH=CH), 6.75 (dd, J 15.6, 10.5, 1H, 
PhCH=CH), 7.18 - 7.23 (1H, m, H-4),  7.28 - 7.32 (2H, m, H-3  & H-5),  7.37 - 7.39 (2H, 
m, H-2  & H-6 ); LRMS (TOF AP+): m/z (rel. int.) 186.1 (M+H-Ac, 100%), 169.1 (M-
AcO, 28%);  HRMS (TOF AP
+
): Acc. MS calc. for C15H17O2
+
 [M+H]
+
, 229.1229; found 
229.1219. 
 
4-Phenylbutyric 2,4,6-trichlorobenzoic anhydride 219 
 
To a solution of 4-phenylbutyric acid 218 (1.87 g, 11.40 mmol) in dry toluene (30 mL) 
under Ar at room temperature was added 2,4,6-trichlorobenzoyl chloride 155 (2.77 g, 11.40 
mmol) and triethylamine (1.59 mL, 11.40 mmol) in toluene (30.0 mL). The resulting 
solution was stirred at room temperature for 22 h. After that time, the mixture was triturated 
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with hexane to precipitate triethylamine hydrochloride as white crystals, which is filtered, 
and the resulting solution concentrated under reduced pressure to give the desired 
compound  219 as a white solid (3.86 g, 87%); Rf  0.52 (hexane : EtOAc, 4:1); Mp = 58-60 
˚C;  max /cm
-1
 (film) 2929 (m, C-H), 1810 (vs, C=O anhydride), 1744 (s), 1575, 1547 
&1494 (m, C=C aromatic), 1241 (m), 1076 (vs), 980 (vs), 750 (vs, C-Cl);  C17H13Cl3O3 
requires C, 54.94; H, 3.53; found C, 54.04; H, 3.40; 
1
H NMR (400 MHz, CDCl3, 20 °C): δH 
1.98 (2H, q, J 7.4, CH2CH2CH2), 2.44 (2H, t, J 7.4, CH2C=O), 2.68 (2H, t, J 7.4, CH2Ph), 
7.16-7.23 (3 H, m, H-4, H-2  & H-6), 7.26-7.32 (2 H, m, H-3 & H-5) and 7.40 (2 H, s, 
=CHCl); 
13
C NMR (101 MHz, CDCl3): δc 25.6 (CH2CH2CH2), 34.4 (CH2C=O), 34.7 
(CH2Ph),126.1 (C-4), 128.3 (2C, =CH-CCl), 128.4 (2C, C-2  & C-6), 128.5 (2C, C-3  & 
C-5),   129.8 (2C, ClCCC=O), 133.1 (2C, =CCl, Ortho position), 137.6 (=CCl, Para 
position), 140.8 (C-1),  157.5 (ClCCC=O);), 169.1 (C-1-C=O); LRMS (EI): m/z (rel. int.) 
207 (C7H3Cl3O-M, 100%). 
 
 (2Z, 4E, 6E)-7-Phenylhepta-2,4,6-trien-2-yl 4-phenylbutanoate 220  
 
  
To a solution of ketone 215 (25 mg, 0.13 mmol) in dry toluene (2 mL) under an atmosphere 
of argon at room temperature, was added Et3N (0.06 mL, 0.40 mmol) and DMAP (2 mg, 
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0.01 mmol). The resulting solution was stirred at room temperature for 10 miutes and then 
the mixed anhydride 6 (50 mg, 0.134 mmol) was added. The reaction is stirred for 24h and 
the solvent removed. The crude product subjected to SiO2 column chromatography (hexane 
:  EtOAc, 7:1, as eluent)  to give the desired product 220 as a yellow thick oil (12 mg, 27%) 
as a mixture of  E and Z enolate  (EEZ:EEE = 8 : 1), which separated by recrystallisation 
with MeOH to give the enol ester 220 as yellow solid (6 mg, 13% ), Mp = 64 – 66 oC, Rf  
0.47 (hexane : EtOAc, 4 : 1); UV λmax
EtOH
 nm (log ε) 208 (3.925), 288 (3.574); max /cm
-1
 
(film) 2929 (m, C-H), 1720 (s, C=O), 1374 (vs), 1301 (vs), 1164 (s), 838 (s), 668 (s);  
1
H 
NMR (400 MHz, CDCl3, 20 °C): H 2.00 (3H, s, MeCH=), 2.02-2.10 (2H, m, CH2), 2.51 
(2H, t, J 7.4, CH2CO), 2.73 (2H, t, J 7.3, PhCH2), 5.74-5.76 (1H, m, H-3), 6.25-6.36 (2H, 
m, H-4 & H-5), 6.53 (1H, d, J 15.5, PhCH=CH), 6.75-6.81 (1H, m, PhCH=CH), 7.18-7.24 
(4H, m, Ar-H),  7.28-7.35 (4H, m, Ar-H),  7.36-7.38 (2H, m, Ar-H ); 
13
C NMR (101 MHz, 
CDCl3): δc 20.1 (C-1), 20.8 (MeCO), 26.5 (CH2CO), 33.5 (CH2), 35.0 (PhCH2), 117.4 (C-
3), 125.6 (C-6), 126.1 (C-2  & C-6), 126.3 (C-2  & C-6) 127.4 (C-4, C-4), 128.4 (C-
3  & C-5 ), 128.5 (C-3  & C-5 ), 132.1 (PhCH=), 132.6 (C-4  & C-5), 137.3 (C-1 & C-
1), 149.6 (=C-O), 171.1 (C=O); LRMS (EI): m/z (rel. int.) 332.2 (M+, 2%), 186.1 (M- 
Ph(CH2)3CO2, 70%), 91.0 (PhCH2-M, 100%). 
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4-Phenylbutyric anhydride 222 
 
 
 
To a solution of ketone 215  (20 mg, 0.11 mmol) in dry toluene (2 mL) under Ar at room 
temperature, was added Et3N (0.02 mL, 0.11 mmol), TMSCl (0.01 mL, 0.11 mmol) and 
ZnCl2 (0.11 mL, 0.11 mmol). The resulting solution was stirred at room temperature for 2h 
and then the mixed anhydride 219 (40 mg, 0.11 mmol) was added. The reaction is stirred 
for 24h and the solvent removed. The crude product subjected to SiO2 column 
chromatography  (EtOAc : petroleum ether, 1 : 9,  as eluent) to give the symmetrical 
anhydride  189 as a white solid (28 mg, 85%): Mp = 34 – 35 oC; 1H NMR (400 MHz, 
CDCl3, 20 °C): δH 1.79 (4H, q, J 7.6, CH2 ), 2.38 (4H, t, J 7.4, CH2CO), 2.68 (4H, t, J 7.4, 
PhCH2), 7.17-7.21 (6H, m, H-2, H-2, H-4, H-4  & H-6, H-6),  7.26-7.31 (4H, m, H-3, 
H-3, H-5, H-5); 13C NMR (101 MHz, CDCl3): δc 26.2 (CH2), 33.0 (CH2CO), 34.9 
(PhCH2), 126.0 (C-4, C-4),  128.4 (C-2, C-2, C-6, & C-6)128.5 (C-3, C-3, C-5 & 
C-5 ), 138.9 (C-1 & C-1), 141.1 (COO); LRMS (AP+): m/z (rel. int.)  311.2 (MH+, 2%), 
164 (MH-C6H5-C3H6-CO, 15%), 147.1 (M-C6H5(CH2)3CO2, 100%). 
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2,4,6-Trichlorobenzoic anhydride 207 
 
To a solution of 4-phenylbutyric acid 185 (1.873 g, 11.41 mmol) in dry toluene (30 mL) 
under Ar at room temperature was added 2,4,6-trichlorobenzoyl chloride 155 (2.772 g, 
11.407 mmol) and triethylamine (1.59 mL, 11.407 mmol) in toluene (30.0 mL). The 
resulting solution was stirred at room temperature for 22 h. After that time, the mixture was 
triturated with hexane to precipitate triethylamine hydrochloride as white crystals, which is 
filtered, and the resulting solution concentrated under reduced pressure and  triturated with 
hexane to give the byproduct compound 207 as a white solid (0.480 g, 10%); Rf 0.38 
(hexane : EtOAc, 4 : 1); Mp = 107 – 108 ˚C. max /cm
-1
 (film) 3073 (m, =C-H), 1811 (s, 
C=O anhydride), 1798 (s, C=O anhydride), 1755, 1740, 1572 &1545 (s, C=C aromatic), 
1369, 1206 (s), 1079 (s), 983 (vs), 858 (vs), 819(s), 764 (C-Cl); C14H4Cl6O3 requires C, 
38.84; H, 0.93; found C, 38.84; H, 0.98; H  (400 MHz, CDCl3) 7.39 (4 H, s, =CH); C (100 
MHz, CDCl3) 128.3 (4C, CH), 129.8 (2C,=CC=O), 133.1 (4C, =CCl, Ortho position), 
137.6 (2C, =CCl, Para position), 157.5 (C=O); LRMS (ESI): m/z (rel. int.)  471 (MK
+
, 
100%), 223 (M-C7H2Cl3O2, 100%). 
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Preparation stock solution of 2,4,6-trichlorobenzoic cyclopentanecarboxylic 
anhydride 242 
 
To a stirred solution of cyclopentane carboxylic acid 241  (3.20 g, 28.04 mmol) in dry 
toluene (80 mL) under Ar at rt, was added 4 ˚A molecular sieves (0.80 g), Et3N (4.30 mL, 
30.84) and 2,4,6-trichlorobenzoyl chloride (6.84 g, 28.04 mmol). The reaction mixture was 
stirred at rt for 18h. The reaction mixture keeped closed under Ar for futher using. 
 
tert-Butyl (1R)-2-hydroxy-1-phenylethylcarbamate 250 
  
 
To a stirring solution of 0.27 g (7.28 mmol, 2.2 eq) of sodium borohydride and dry THF 
(150 mL) at 0 °C is added 1.84 g (7.28 mmol, 2.2 eq) of iodine in 6 ml of dry THF. The 
iodine-THF solution was added dropwise to the borohydride-THF suspension.  After that, 
0.50 g (3.31 mmol, 1eq) of (R)-phenylglycine 249 was added to the mixture in one portion. 
The reaction was heated at reflux for 18 h. After this period, the reaction was cooled to 0 
C and 0.60 ml of methanol was added to the reaction, then diluted with 5 ml of dry THF 
and 0.48 ml (3.47 mmol, 1.05 eq) of triethylamine was added in one portion. With vigorous 
stirring 0.73 g (3.34 mmol, 1.01 eq) di-tert-butyl dicarbonate is added in one portion. The 
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reaction was allowed to warm to room temperature further than 48h. The solvents were 
removed and the resulting white solid was suspended by adding 4 ml of ethyl acetate and 3 
ml of water. The white residue was broken down by addition 10% aq. HCl and brine. The 
aqueous phase is extracted with ethyl acetate (3 x 10 ml) and the combined organic phases 
were washed with: a) a 1:1 solution of 5% HCl and brine (8 ml); b) a 1:1 solution of 
saturated NaHCO3 and brine (8 ml); and finally c) water (8 ml). The organic phase was 
dried over MgSO4. The solvent was removed in vacuo to leave 1.10 g of crude product that 
recrystallized using cyclohexane and DCM system to give the desired product 250 (0.56 g, 
72%) as white needles: Mp 136-137C, lit. value 138-139 C (from cyclohexane/ DCM);158 
[]21D -40.0 (c 1.0, CHCl3), lit. value -41.9 (c 1.0, CHCl3);
158
 C13H19NO3 requires C, 
65.85; H, 8.03; N, 6.03 found C, 65.80; H, 8.07; N, 5.90;  νmax/cm-1 ( KBr disk) 3233 
(broad, -OH), 3061(broad, N-H), 1675 (strong, C=O); 
1
H NMR (400 MHz, CDCl3): H 1.40 
(9H, s, Me3CO), 1.90 (1H, broad, exchanges with D2O, OH), 3.86 (2H, d, J  4.1, CH2OH), 
4.85 ((1H, brd, CHPh), 5.32 ((1H, brd, NH), 7.26-7.31 (3H, m, H-2ʹ, H-4ʹ & H-6ʹ), 7.33-
7.38 (2H, m, H-3ʹ & H-5ʹ); 13C NMR (400 MHz, CDCl3): c 28.3 (Me3CO), 37.5 (CHPh), 
71.2 (CH2), 79.9 (quaternary, Me3CO),  126.7, 128.3, 128.9, 137.7 (quaternary, C-1ʹ), 155.0 
(quaternary, C=O); LRMS (ES
+
): m/z (rel. int.) 238.2 (MH
+
, 25%); 223.2 (MH
+
-Me, 
100%), 182.2 (MHNa
+
-C6H5, 75%);; Enantiomeric excess was determined by HPLC (e.e. ≥ 
99.8%) with a Chiralpak OD column (90:10, hexane:ethanol), 0.5 mL/min;  = 235 nm; R-
enantiomer tR = 13.85  min, S-enantiomer tR = 15.66 min. 
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(2R)-2-[(tert-Butoxycabonyl) amino]-2-phenylethylmethanesulfonate. 
 
 To a stirred solution of 0.50 g (2.11 mmol, 1 eq ) of  tert-butyl  (1R)-2-hydroxy-1-
phenylethylcarbamate 250 in dry DCM (10 mL) under argon is added 0.44 mL of freshly 
distilled triethylamine  (3.16 mmol,  1.5  eq ) then cooled to 0 C. Then, 0.17 ml (2.2 mmol, 
1.05 eq) of methanesulfonyl chloride in 5 mL of dry DCM is added dropwise. The reaction 
was stirred at <20 °C for 12 h, after this time 4 mL of saturated NaHCO3 was added. After 
stirring for a further 20 min, the aqueous phase was diluted with DCM (2 x 10 mL) and the 
combined organic phases washed with saturated sodium chloride solution (2 x 5 mL). After 
drying the organic phase (MgSO4), the solvents were removed in vacuo to yield 0.67 g of 
an off-white solid that was recrystallised from DCM-hexane to give 0.47 g (71%) of (2R)-
2-[(tert-butoxycarbonyl)amino]-2-phenylethyl methanesulfonate 254 as  a white solid: 
m.p.111-113 C, lit. value 112-114 C (from cyclohexane/ DCM);159a []21D -21 (c 1.0, 
CHCl3), lit. value -21 (c 1.0, CHCl3);
159b
 C14H21NO5S requires C, 53.15; H, 6.75; N, 
4.38%; found C, 53.32; H, 6.71; N, 4.44%; 
1
H NMR (400 MHz, CDCl3) H 1.43 (9H, s, 
Me3CO), 2.87 (3H, s, MeSO3), 4.38-4.49 (2H, m, CHCH2), 5.02 (1H, bs, PhCH), 5.16 (1H, 
brs, exchanges with D2O, NH), 7.31-7.33 (3H, m, H-2ʹ, H-4ʹ & H-6ʹ), 7.36-7.40 (2H, m, H-
3ʹ & H-5ʹ); 13C NMR (400 MHz, CDCl3) c 28.3 (Me3CO), 37.4 (CHPh), 71.2 (CH2), 79.9 
(quaternary, Me3CO),  126.7, 128.3, 128.9, 137.7 (quaternary, C-1ʹ), 155.0 (quaternary, 
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C=O); ; LRMS (ES
+
): m/z (rel. int.) 301.2 (MH
+
-Me, 92%), 260.2 (MNaH
+
-MeSO2, 100%). 
 
tert-Butyl(1R)-2-cyano-1-phenylethylcarbamate 255 
 
 
 
To a 0.45 g (1.43 mmol) of (2R)-2-[(tert-butoxycarbony)amino]-2-
phenylethylmethanesulfonate 254 in anhydrous DMSO (10 ml)  under argon, is added  0.28 
g (5.50 mmol, 4 eq) NaCN in one portion. The reaction was stirred at 45 °C for 18h. The 
reaction is then cooled to 0 °C and 10 mL of water added. The DMSO-H2O phase extracted 
with diethyl ether (3 X 10 mL). The combined ether Extracts are then washed with 
saturated NaCl (3 x 25 mL), water (2 x 25 mL) and dried (MgSO4). Removal of the solvent 
in vacuo gives a white solid that is recrystallised from DCM-hexane to yield 0.26 g (84%) 
of tert-butyl (1R)-2-cyano-1-phenylethycarbamate 255 as white crystals. Mp 114 – 115 C, 
lit value 110-112 °C;
160 
[]21D -42.1(c 0.5, EtOH), lit. for S-enantiomer []
21
D +41.6° (c 
0.5, EtOH);
160 
C14H18N2O2 requires C, 68.01; H, 7.29; N, 10.94% found C, 68.27; H, 7.37; 
N, 11.37%; 
1
H NMR (400 MHz, CDCl3): H 1.45 (9H, s, Me3CO), 2.89 (1H, dd, J 16.4, 
6.2, CHHCN), 2.99 (1H, dd, J 16.4, 6.2, CHHCN), 4.99 (2H, bd, J 5.7, exchanges with 
D2O, NH, PhCH), 7.33-7.37 (3H, m, H-2ʹ, H-4ʹ & H-6ʹ), 7.39-7.43 (2H, m, H-3ʹ & H-5ʹ); 
13
C NMR (400 MHz, CDCl3): c 26.9 (CH2), 28.3 (9H, s, Me3CO), 80.6 (quaternary, ), 
117.0 (quaternary, CN), 126.2, 128.7, 129.2, 139 (quaternary, C-1ʹ);); LRMS (CI): m/z (rel. 
  126 
int.) 246.6 (M
+
, 7%), 206.2 (MH-Me-CN, 57%), 206.2 (M-Me2-CN, 100%);  Enantiomeric 
excess was determined by HPLC (e.e. ≥99.8%) with a Chiralpak OJ column (95:5 
hexane:2-propanol), 0.75 mL/min;  = 254 nm; R-enantiomer tR = 44.37 min, S-
enantiomer tR = 35.25 min. 
 
tert-Butyl (1R)-3-oxo-1-phenylpropylcarbamate 256
 
 
tert-Butyl(1R)-2-cyano-1-phenylethylcarbamate 255 (10.20 g, 41.41 mmol) was dissolved 
in dry ether (150 mL), cooled to -42 °C and stirred under argon. Dibal-H was added 
(165.65 mL, 1M solution in PhMe, 165.65 mmol) over 15 min. The mixture was stirred for 
30 minutes, and methanol (6 mL) followed by saturated NH4Cl (150 mL). After allowing 
the mixture to warm to room temperature, the thick gel was quenched by the slow addition 
of 5% HCl (150 mL). The aqueous layer was extracted with EtOAc (3 x 30 mL), and the 
organic layer washed with 5% HCl and brine (2 x 25 mL of each), saturated NaHCO3and 
brine (2 x 25 mL of each), and dried (MgSO4). Evaporation gave tert-butyl (1R)-3-Oxo-1-
phenylpropylcarbamate 256 (10.12 g, 98%) as a yellow solid; Mp 82-85 °C (lit.
152
 value 
91-93°C); []21D -26.1° (c 0.08, CHCl3), lit. for S-enantiomer []
21
D +27.5° (c 0.08, 
CHCl3);
161
 Rf 0.35 (hexane: EtOAc, 4:1); 
1
H NMR (400 MHz, CDCl3):H 1.37 (9H, s, 
Me3CO),  2.83-2.97 (2H, m, CH2CHO), 5.09 (1H, brd,  CHPh),  5.15 (1H, brs, NH signal 
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exchanges with D2O), 7.21-7.27 (3H, m, H-2ʹ, H-4ʹ & H-6ʹ), 7.28-7.32 (2H, m, H-3ʹ & H-
5ʹ), 9.70 (1H, dd, J 2.5, 1.6 Hz, CHO); 13C NMR (100 MHz, CDCl3): c 28.3 (Me3CO), 
49.9 (CH2CHO), 54.5 (CHPh), 126.3 (C-2ʹ & C-6ʹ), 127.7 (C-4ʹ), 128.1 (C-3ʹ & C-5ʹ), 
143.8 (C-1ʹ, quaternary), 154.9 (Me3C=O), 200.0 (CHO). Spectroscopic and analytical 
properties were identical to those reported in the literature.
152
 
 
Iodomethyltriphenylphosphonium iodide 145 
 
 
To a suspension of triphenylphosphine 223 (5.0 g, 19.06 mmol) in dry DCM (50 mL) was 
added diiodomethane 257 (6.14 mL, 4 eq). The mixture was stirred at rt for 18h, 
concentrated in vacuo and the crystals were collected by filtration. After washing with 
hexane, and drying in vacuo (0.1 mmHg), iodomethyltriphenylphosphonium iodide 145 
(8.78 g, 87%) was isolated as a white solid, Mp 226-229°C (dec) (Lit.
162
 230 °C (dec); 
1
H 
NMR (400 MHz, DMSO, 20 °C): δH 5.13 (2H, d, J 8.8, CH2), 7.80-7.98 (15H, m, (C6H5)3); 
13
C NMR (101 MHz, DMSO): δC 40.4 (CH2), 130.6 (C-3ʹ & C-5ʹ), 130.7 (C-3ʹ & C-5ʹ), 
134.3 (C-2ʹ & C-6ʹ), 134.4 (C-2ʹ & C-6ʹ), 135.6 (C-4ʹ), 135.7 (C-4ʹ). Spectroscopic and 
analytical properties were identical to those reported in the literature.
162
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tert-Butyl N-[(Z,1R)-4-iodo-1-phenylbut-3-enyl]carbamate 258
 
 
To a suspension of iodomethyltriphenylphosphonium iodide 145 (475 mg, 0.90 mmol) in 
THF (10 mL) at room temperature was slowly added lithium hexamethyldisilazide (1.0 M 
solution in THF, 1.79 mL, 1.80 mmol). After stirring for 10 min, the dark red-colored 
solution was cooled to −78 °C and HMPA (0.57 mL, 3.26 mmol) was added. A solution of 
aldehyde 256 (203 mg, 0.81 mmol) in THF (5 mL) was added slowly and the mixture was 
allowed to warm up to room temperature and, after 20 min, the reaction was quenched with 
sat. NH4Cl (5 mL) and filtered. The resulting solution was extracted with ether (3 x 20 mL). 
The combined organic extracts were washed with brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. The residue was purified by SiO2 chromatography (EtOAc : 
petroleum ether, 1 : 19, as eluent) to give tert-Butyl N-[(Z,1R)-4-iodo-1-phenylbut-3-
enyl]carbamate 258 (122 mg, 40%) as white solid (30:1 Z:E isomers could not be 
separated); Rf  0.50 (hexane : EtOAc, 4 : 1); Mp 103-105°C (lit.
127c
 value 104-106°C); 
[]21D -25.3° (c 1.2, CHCl3), lit. for S-enantiomer []
21
D +27.9° (c 0.08, CHCl3);
127c
 
1
H 
NMR (400 MHz, CDCl3): δH 1.42 (9H, s, Me3CO), 2.63 (2H, br, CH2CHPh), 4.86 (2H, br, 
CHPh & NH), 6.11 (1H, dd, J 13.7, 7.5, =CHCH2), 6.33 (1H, d, J 7.5, =CHI), 7.20 – 7.26 
(3H, m, H-4ʹ, H-2ʹ & H-6ʹ), 7.33 – 7.37 (2 H, m, H-3ʹ & H-5ʹ);  
13
C NMR (101 MHz, 
CDCl3): δc 28.3 (Me3CO), 41.9 (CH2), 53.5 (PhCH), 85.2 (CHI),  126.3 (C-2ʹ & C-6ʹ), 
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127.5 (C-4ʹ), 128.6 (C-3ʹ & C-5ʹ),  137.1 (=CHCH2), 142.1 (C-1ʹ, quaternary), 155.1 
(C=O); Spectroscopic and analytical properties were identical to those reported in the 
literature.
127c
 
 
tert-Butyl (1R, 3Z, 5E)-1-phenyl-6-(4,4,6-trimethyl-1,3,2-dioxaborinan-2-yl)-3,5-
hexadienylcarbamate 133
 
 
To a dried Schlenk tube under a positive pressure of argon was added silver(I) acetate (48 
mg, 0.29 mmol), Pd(OAc)2 (3 mg, 0.01 mmol), tri(o-tolyl)phosphine (8 mg, 0.03 mmol), 
vinylboronate (0.05 mL, 0.0.29 mmol), and a (Z)-alkenyl iodide 258 (100 mg, 0.268 mmol) 
in dry MeCN (5 mL). The mixture was degassed using the freeze-pump-thaw method (3 x), 
and heated to 50 °C with vigorous stirring. After 21h, the mixture was cooled, diluted with 
Et2O (25 mL) and passed through Celite, washed with 5% HCl (20 mL), water (20 mL), 
and brine (20 mL), dried (MgSO4), and evaporated to give crude product as a yellow oil. 
Purification by SiO2 chromatography (EtOAc : petroleum ether, 1 : 9 as eluent) gave the 
desired product 133 (78 mg, 73%, 19:1 ZE:EE) as a thick orange oil; Rf 0.32 (hexane: 
EtOAc, 4:1); [α]21D -157.8 (c 9.5, CHCl3);  
1
H NMR (400 MHz, CDCl3):H 1.28 (3H, d, J 
6.3, BOCHMe), 1.30 (6H, d, J 1.7 Hz, BOCMe2), 1.40 (9H, s, Me3CO), 1.50 (1H, dd, J 
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13.9, 11.8 Hz, BOCCHCHH), 1.79 (1H, dd, J 13.9, 2.9 Hz, BOCCHCHH), 2.71-2.75 (2H, 
m, CH2CH=), 3.82 - 3.88 (1H, m, CHOBO), 4.18 - 4.24 (1H, m, CHOB), 4.78 (1H, brs, 
CHPh), 4.85 (1H, brs, NH signal exchanges with D2O), 5.36-5.44 (1H, m, CH=CHB), 5.50 
(1H, d, J 17.3 Hz, =CH-CH=CHB), 6.14 (1H, t, J  11.3 Hz, CH2-CH= ), 7.13 (1H, dd, J 
17.4, 11.3 Hz, CH2-CH=CH), 7.22-7.35 (5H, m, C6H5); 
13
C NMR (101 MHz, CDCl3): c 
23.1 (MeCHOB), 28.1 (Me2COB), 28.3 (Me3CO), 31.2 (boronate CH2), 46.0 (CH2CHPh), 
54.4 (CHPh), 64.7 (BOCHMe), 70.8 (BOCMe2), 77.2 (Me3CO), 126.2 (C-2ʹ & C-6ʹ), 126.4 
(=CH), 127.1 (C-4ʹ), 128.5 (C-3ʹ & C-5ʹ), 128.9 (=CH), 133.6 (CH2CH=), 139.3 (C-1ʹ, 
quaternary), 155.2 (C=O); B (128 MHz, CDCl3) 26.07. Spectroscopic and analytical 
properties were identical to those reported in the literature.
127c 
 
tert-Butyl(1R, 3Z, 5E, 7E)-10- tert-Butyldimethylsiloxy-1-phenylundeca-3,5,7-
trienylcarbamate
  
259 
 
To a dried Schlenk tube under a positive pressure of argon was added (Z)-alkenyl iodide 
258 (95 mg, 0.25 mmol) and dialkenyl boronate 175 (99 mg, 0.28 mmol) in DMF (4 mL) 
and H2O (0.4 mL). The mixture degassed using the freeze-pump-thaw method (3 x), and 
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Ba(OH)2 ( 52 mg, 0.31 mmol) and Pd(dppf)Cl2.CH2Cl2 (10 mg, 0.01 mmol) were added, 
and then the mixture was degassed using the freeze-pump-thaw method (3 x ). The mixture 
was vigorously stirred at 45 °C with vigorous stirring for 48h before it was diluted with 
EtOAc (25 mL) and passed through Celite, washed with 5% HCl (20 mL), water (20 mL), 
and brine (20 mL), dried (MgSO4), and evaporated to give crude product as a brown oil. 
Purification by SiO2 chromatography (EtOAc : petroleum ether, 1 : 9, as eluent) gave the 
desired product 259 as yellow oil (84 mg, 71%); Rf  0.73 (hexane : EtOAc, 4 : 1); [α]
21
D -
285.7 (c 1.4, CHCl3); UV λmax
EtOH
 nm (log ε) 204 (4.063), 272 (4.389), 284 (4.309), 304 
(3.775), 320 (3.695); λmax /cm
-1
 (film) 2924 (s), 2870 (m), 1700 (s, C=O), 1494 (m), 1363 
(s), 1253 (s), 996 (s), 729 (vs); 
1
H NMR (700 MHz, CDCl3, 20 °C): δH 0.04 (6H, s, MeSi ), 
0.88 (9H, s, Me3CSi), 1.12 (3H, d, J 6.1, MeCHOSi), 1.41 (9H, s, Me3CO), 2.16-2.29 (2H, 
m, CH2CHOSi), 2.59-2.73 (2H, m, CH2CHPh), 3.83 (1H, q,  J  6.1 Hz,CHOSi), 4.76 (1H, 
brd,  CHPh),  4.84 (1H, brs, NH signal exchanges with D2O), 5.28 (1H, dt, J  15.0, 7.5, 
=CHCH2CHOSi), 5.71 (1H, dt, J  15.0, 7.5 Hz, =CHCH2CHPh), 6.10 (2H, t, J 12.2 Hz, H-  
& H-3),  6.19 (1H, dd, J  14.4, 11.4 Hz, =CH), 6.32 (1H, dd, J  14.4, 11.4 Hz, =CH), 7.22-
7.27 (3H, m, H-4ʹ, H-2ʹ & H-6ʹ), 7.31-7.35 (2H, m, H-3ʹ & H-5ʹ); 13C NMR (101 MHz, 
CDCl3): δc -4.7 (MeSi), -4.5 (MeSi), 18.1 (Me3CSi), 23.5 (MeCHOSi), 25.9 (Me3CSi), 28.3 
(Me3CO), 35.0 (CH2Ph), 43.2 (CH2CHOSi), 68.6 (CHOSi), 79.5 (Me3CO), 125.7 (=CH), 
126.0 (=CH), 126.3 (=CH), 127.2 (=CH), 128.5 (=CH), 130.9 (=C-), 131.5 (=CH), 132.2 
(=CH), 132.4 (=CH), 134.1 (=CH), 155.2 (C=O); LRMS (ESI): m/z (rel. int.) 494.4 (MNa
+
, 
100%); LRMS (AP
+
): m/z (rel. int.) 472.3 (MH
+
, 5%), 372.3 (MH2
+
-Boc, 100%); 240.2 
(MH
+
-Boc-OTBS, 25%); 159.1 (M
+
-Boc-OTBS-C6H6-H2, 37%); HRMS (TOF AP
+
): Acc. 
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MS calc. for C28H46NO3
28
Si
+
 [M+H]
+
, 472.3247; found 472.3253. 
 
tert-Butyl (1R, 3Z, 5E, 7E)-10-hydroxy-1-phenylundeca-3,5,7-trienylcarbamate 262 
 
The triene compound 259 (182 mg, 0.37 mmol) is dissolved in THF and TBAF (1.54 mL, 
1.54 mmol, 1M solution in THF, 4 eq) was added drop wise at RT. The result mixture is 
stirred until the consumption of starting material by TLC.  The reaction mixture is diluted 
with EtOAc (25 mL), washed with brine (20 mL), water (20 mL), and  dried over MgSO4, 
concentrated in vacuo. Purification of the residue by SiO2 chromatography (EtOAc : 
petroleum ether, 1 : 9, as an eluent) gave the allylic alcohol 262 as yellow oil (112 mg, 
81%); Rf  0.84 (hexane: EtOAc, 1:1); [α]
21
D -352.9 (c 1.7, CHCl3); UV λmax
EtOH
 nm (log ε) 
244 (3.581), 272 (3.841), 284 (3.815), 300 (3.667), 316 (3.629), 328 (3.221), 348 (3.071); 
λmax /cm
-1
 (film) 3386 (br, OH), 2924 (s), 2870 (m), 1685 (vs, C=O), 1507 (m), 1365 (s), 
1248 (s), 1166 (vs), 700 (vs);  
1
H NMR (400 MHz, CDCl3, 20 °C): δH 1.21 (3H, d, J 6.2, 
MeCHOH), 1.41 (9H, s, Me3CO), 1.52 (1H, brs, OH, exchanges with D2O), 2.19-2.34 (2H, 
m, CH2CHOH), 2.59-2.73 (2H, m, CH2CHPh), 3.81-3.90 (1H, m, CHOH), 4.75 (1H, brs, 
CHPh), 4.84 (1H, brs, NH signal exchanges with D2O), 5.31 (1H, dt, J  15.1, 7.6, 
CH2CH=), 5.71 (1H, dt, J  14.0, 7.4, =CHCH2CHPh), 6.06-6.23 (3H, m, =CH), 6.36 (1H, 
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dd, J  12.3, 7.2, =CH), 7.22-7.27 (3H, m, H-4ʹ, H-2ʹ & H-6ʹ), 7.31-7.34 (2H, m, H-3ʹ & H-
5ʹ); 13C NMR (101 MHz, CDCl3): δc 22.9 (MeCHOH), 28.3 (Me3CO), 35.0 (CH2CHPh), 
42.4 (CH2CHOH), 54.5 (CHPh), 67.7 (CHOH), 77.2 (Me3CO), 126.3, 127.2, 128.5, 133.5, 
133.6, 188.7 (C=O); LRMS (ESI): m/z (rel. int.) 381.3 (MHNa
+
, 23%); 380.3 (MNa
+
, 
100%); 358.0 (MH
+
, 4%); HRMS (ES
+
): Acc. MS calc. for C22H31NNaO3 [M+Na]
+
, 
380.2202; found 380.2180.  
 
Attempted synthesis of tert-butyl(1R,3Z,5E,7E)-10-oxo-1-phenylundeca-3,5,7-
trienylcarbamate 263 
  
To a solution of 262 (170 mg, 0.48 mmol) in dry DCM (10 mL) under Ar at 0 C was 
added NaHCO3 (120 mg, 1.43 mmol, 3 eq) and Dess-Martin periodinane (403 mg, 0.95 
mmol, 3 eq). The resulting mixture was stirred for 3 h at 0 ºC before a saturated aqueous 
Na2S2O3 solution (6 mL) was added. After being stirred for 10 min, the mixture was 
extracted with ether (20 mL x 3). The combined organic layers were washed with brine (20 
mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was dissolved in 
DCM, passed through silica-gel, and evaporated to provide the allylic ketone 263 (89 mg, 
53%) as a mixture of ZEE/ZEZ/ZEEE (67:11:10); λmax /cm
-1
 (film) λmax /cm
-1
 (film) 2926 
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(s), 1702 (vs, C=O), 1494 (m), 1366 (s), 1251 (s), 742 (s), 699 (s); 
1
H NMR (400 MHz, 
CDCl3, 20 °C): δH 1.40 (9H, s, Me3CO), 2.16 (3H, s, MeCO), 2.54 (1H, br, CHHCHPh), 
2.67 (1H, br, CHHCHPh), 3.32  (2H, d,  J  7.4, CH2CO), 4.74 (1H, brs, CHPh), 4.88 (1H, 
brs, NH), 5.33 (1H, dt, J 11.1, 7.9, =CHCH2CO), 5.50-5.58 (1H, m, CH2CH=), 5.78 (1H, 
dt, J 14.6, 7.4, =CHCH2CHPh), 6.02-6.24 (3H, m, =CH),  6.30-6.34 (1H, m, =CH), 7.22-
7.34 (5H, m, C6H5). 
 
(4E,6E)-7-(4,4,6-Trimethyl-1,3,2-dioxaborinan-2-yl)hepta-4,6-dien-2-ol  264 
 
 
To a solution of substrate 178 (512 mg, 1.45 mmol) in MeOH (40 mL) under Ar at rt, was 
added DOWEX 50 WX8 200 mesh (400 mg). The reaction left to stir at rt for 18 h. TLC 
indicated that there is some of substrate so another quantity of DOWEX 50 WX8 200 mesh 
(983 mg) was added. After 3h of stirring at rt, the TLC indicated consumed of the starting 
material. The reaction mixture is filtered and evaporated. Purification of the residue by 
SiO2 chromatography (EtOAc : petroleum ether, 1 : 3, as eluent) gave the desired product 
264 (241 mg, 70%); Rf 0.83 (hexane : EtOAc, 1:1); UV λmax
EtOH
 nm (log ε) 204 (3.697), 244 
(3.927), 277 (3.294); λmax /cm
-1
 (film) 3343 (br, OH), 2970 (m), 2929 (w), 1387 (s, C=C), 
1302 (vs), 1008 (s); 
1
H NMR (400 MHz, CDCl3, 20°C): δH 1.18 (3H, d, J 6.1, CHMe), 1.26 
(3H, d, J 6.1, BOCCHMe ), 1.29 (6H, s, BOCMe2), 1.48 (1H, dd, J 13.8, 11.6, 
BOCCHCHH), 1.63 (br, OH), 1.77 (1H, d, J 13.8, 2.9 Hz, BOCCHCHH), 2.18-2.32 (2H, 
m, CH2CH=CH), 3.80-3.88 (1H, m, CHOH), 4.21 (1 H, dqd, J 12.3, 6.2, 2.9, CHOBO), 
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5.42 (1H, d, J 17.5, 1H, CH=CHB), 5.81 (1H, dt, J 15.1, 7.4, CH2CH=), 6.19 (ddd, J 15.1, 
10.4, 0.8, 1H,CH=CH=CHB); 6.91 (dd, J 17.5, 10.4, 1H, CH=CH=CHB); 
13
C NMR (101 
MHz, CDCl3): δc 22.8 (MeCHOH), 23.1 (MeCHOB), 28.1 (Me2COB), 31.2 (CH2CH=), 
42.6 (CH2OH), 46.0 (boronate CH2), 64.7 (CHOH), 67.3 (BOCMe2),  70.7 (MeCHOB), 
132.7 (=CH), 135.8 (=CH), 146.5 (CH2CH=); δB (128 MHz, CDCl3) 25.99; LRMS (TOF 
AP
+
): m/z (rel. int.) 239.2 (MH
+
, 50%), 195.2 (M
+
-Me2CH2, 100%); HRMS (TOF AP
+
): 
Acc. MS calc. for C13H24
10
BO3
+
 [M+H]
+
, 238.1855; found 238.1842. 
 
 
(4E,6E)-7-(4,4,6-Trimethyl-1,3,2-dioxaborinan-2-yl)hepta-4,6-dien-2-one 265 
 
 
To a solution of substrate 264 (0.44 g, 1.48 mmol) in DCM (40 mL) under Ar at 0 ºC were 
added NaHCO3 (1.55 g, 2.55 mmol), Dess-Martin periodinane (1.175 g, 2.77 mmol) and 
tert-butanol (0.14 mL, 1.48 mmol). The resulting mixture was stirred for 4 h at 0 ºC. The 
crude product was filtered, evaporated and subjected to silica gel chromatography (EtOAc : 
petroleum ether,  1 : 4, as eluent) to give the desired product 265 as yellow oil (0.375 g, 
86%); Rf  0.31 (hexane : EtOAc, 1 : 4); UV λmax
EtOH
 nm (log ε) 200 (3.704), 244 (3.986), 
276 (3.327);  λmax /cm
-1
 (film) 2973 (m), 1712 (s, C=O), 1372 (vs, C=C), 1304 (vs), 1162 
(s); 
1
H NMR (400 MHz, CDCl3, 20°C): 1.26 (3H, d, J  6.1, BOCCHMe ), 1.29 (6H, s, 
BOCMe2), 1.49 (1H, dd, J 13.8, 11.7, BOCCHCHH), 1.78 (1H, dd, J 13.8, 2.9 Hz, 
BOCCHCHH), 2.14 (3H, s, MeCO), 2.18-2.32 (2H, m, CH2CH=CH), 3.20 (2H, d, J 7.6, 
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CH2CO), 4.17-4.25 (1H, m, CHOBO), 5.45 (1H, d, J 17.5, 1H, CH=CHB), 5.89 (1H, dt, J 
15.2, 7.3, CH2CH=), 6.17 (ddd, J 15.2, 10.4, 0.8, 1H,CH=CH=CHB); 6.91 (dd, J 17.5, 
10.4, 1H, CH=CH=CHB); 
13
C NMR (100 MHz, CDCl3, 20°C): δc 23.1 (MeCHOB), 28.09 
(Me2COB), 31.2 (CH2CH=), 42.5 (CH2OH), 45.9 (boronate CH2), 64.6 (CHOH), 67.2 
(BOCMe2),  70.7 (MeCHOB), 132.7 (=CH), 135.8 (=CH), 146.5 (CH2CH=); δB (128 MHz, 
CDCl3) 25.99; LRMS (TOF AP
+
): m/z (rel. int.) 237.2 (MH
+
, 100%), 236.2 (M
+
, 20%);  
HRMS (TOF AP
+
): Acc. MS calc. for C13H22
10
BO3
+
 [M+H]
+
, 236.1698; found 236.1673. 
 
Ammonium [(Z,1R)-4-iodo-1-phenylbut-3-enyl] trifluoroacetate 271 
 
 
To a solution of substrate 258 (26 mg, 0.07 mmol) in DCM (0.5 mL) at 0 ºC was added 
TFA (0.5 mL). After 20 min of stirring the reaction mixture at 0 ºC, the TLC indicated the 
consumption of the substrate. Toluene (5 mL) was added to the reaction mixture and the 
TFA was removed by evaporation. Another 5 mL of toluene was added and the solvent was 
trapped on rotary. The brown oily product (25 mg, 96%) was indicated by 
1
H NMR as the 
desired ammonium TFA salt 271; 
1
H NMR (400 MHz, CDCl3, 20 °C): δH  2.71-2.83 (2H, 
m, CH2CHPh), 4.19 (1H, t, J 7.6, CHPh), 5.98 (1H, dd, J  14.2, 7.0, =CH), 6.37 (1H, d, J    
7.6, =CH), 7.14-7.18 (2H, m, Ph), 7.34-7.36 (2H, m, Ph), 8.08-8.57 (3H, brd,  NH3) ); 
13
C 
NMR (101 MHz, CDCl3): δC (101 MHz, CDCl3) 39.0 (CH2Ph), 54.4 (CHPh), 87.0 (=CHI), 
127.0 (C-4ʹ), 127.3  (C-3ʹ & C-5ʹ), 129.0 (C-2ʹ & C-6ʹ), 135.3 (=CHCH2), 162.2 (C=O); 
19
F 
  137 
(376 MHz, CDCl3) δF -75.52. 
 
 
(1R,3Z)-N-(4-iodo-1-phenylbut-3-enyl)acetamide 272 
 
 
To a stirred solution of TFAA salt 271 (37 mg, 0.10 mmol) in dry toluene (1 mL) was 
added Et3N (0.08 mL, 0.57 mmol) and acetic anhydride (0.01 mL, 0.12 mmol). After 24h, 
the reaction mixture was trapped on rotatory and then on high vacuum to give the crude 
product which purified by SiO2 chromatography (EtOAc : petroleum ether, 1 : 3, as eluent) 
to give the desired product 272 as white solid (36 mg, 94%): Mp = 89 – 90 oC; Rf  0.04 
(hexane : EtOAc, 4 : 1); [α]21D -289.8° (c 1.38, CHCl3); λmax /cm
-1
 (film) 3279 (s, NH), 
2924 (m), 1643 (s, C=O), 1551 (s), 1493 and 1433 (m, C=C), 751 (s), 696 (vs); 
1
H NMR 
(400 MHz, CDCl3): δH  1.95 (3H, s, Me), 2.55 – 2.71 (2H, m, CH2CHPh), 5.16 (1H, dd, J 
14.7, 8.2, CHPh), 5.91 (1H, d, J  7.8, NH), 6.11 (1H, dd, J 14.2, 6.9, =CH ), 6.29 (1H, dt, J 
7.5, 1.3,  =CHI), 7.20 – 7.26 (3H, m, H-4ʹ, H-2ʹ & H-6ʹ), 7.27 – 7.34  (2 H, m, H-3ʹ & H-
5ʹ);  
13
C NMR (101 MHz, CDCl3): δc 23.3 (MeCO), 41.0 (CH2), 52.1 (PhCH), 85.5 (CHI),  
126.5 (C-4ʹ), 128.8 (C-2ʹ & C-6ʹ), 127.7 (C-3ʹ & C-5ʹ), 137.1 (=CHCH2), 140.9 (C-1ʹ, 
quaternary), 169.7 (C=O); LRMS (ES
+
): m/z (rel. int.) 338.1 (MNa
+
, 100%), 316.2 (MH
+
, 
50%); HRMS (TOF ES
+
): Acc. MS calc. for C12H15NOI
 +
 [MHNa]
+
, 316.0198; found 
316.0203. 
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Attemp to synthesis (1R,3Z,5E,7E)-10-(tert-Butyldimethylsilyloxy)-1-phenylundeca-
3,5,7-trien-1-amine 270 
 
 
 
To a dried Schlenk tube under argon were added TFAA salt 271 (100 mg, 0.268 mmol), 
dialkenyl boronate 175 (104 mg, 0.295 mmol) and Ba(OH)2 ( 505 mg, 2.948 mmol) in 
DMF (10 mL) and H2O (1 mL). The mixture was degassed using the freeze-pump-thaw 
method (3 x), and Pd(dppf)Cl2.CH2Cl2 (14 mg, 0.013 mmol) was added. The mixture was 
again degassed using the freeze-pump-thaw method (3 x ) and stirred vigorously at 45 ºC 
for 48h before being diluted with Et2O (50 mL), passing through Celite, and washing with 
brine (40 mL). The aqueous layer was extracted with Et2O (2 x 25 mL) and the combined 
organic extracts were washed  with brine (3 x 25 mL),  dried (MgSO4) and evaporated to 
give crude product 270 (100 mg); λmax /cm
-1
 (film) 3378 (br), 2955 (m), 2928 (m), 2856 
(m), 1605 (m), 11361 (s), 1252 (s), 1144 (s), 833 (vs), 774 (vs); 
1
H NMR (400 MHz, 
CDCl3, 20 °C): δH 0.03 (6H, s, Me2Si ), 0.88 (9H, s, Me3CSi), 1.12 (3H, d, J 6.1, 
MeCHOSi), 2.18-2.27 (2H, m, CH2CHOSi), 2.49-2.98 (2H, m, CH2CHPh), 3.82 (1H , dd, J 
12.2, 6.1, CHOSi)  3.94 – 4.07 (1H, m,  CHPh), 5.34-5.41 (1H, m, =CH), 5.69 (1H, dt, J 
14.7 & 7.5, =CHCH2), 5.64-5.73 (1H, m, =CH), 6.07-6.25 (3H, m, =CH), 6.39 (1H, dd, J  
14.3, 11.3) 7.39 – 7.18 (5 H, m, C6H5). 
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Trifluoromethyl (1R,3Z,5E,7E,10RS)-10- tert-butyldimethylsiloxy-1-phenylundeca-
3,5,7-trienylcarbamate 273
   
 
 
To a stirred solution of substrate 270 (288 mg, 0.775 mmol)  in DCM (12 mL) at 0 °C 
under Ar, was added Et3N (20.33 mL, 2.325 mmol)  and TFAA (0.20 mL, 1.162 mmol). 
The reaction mixture was stirred for 2h, then the reaction mixture diluted Et2O (25 mL) and 
washed water (20 mL). Th e aqoueous layer extracted with Et2O (2 x 25 mL), dryied 
(MgSO4) and evaporated to give the crude product which purified by silica gel column 
chromatography (EtOAc : petroleum ether, 1 : 9, as an eluent) to give the desired product 
273 as as yellow oil (261 mg, 65%); Rf  0.71 (hexane : EtOAc, 4:1); [α]
21
D -44.4° (c 13.5, 
CHCl3); UV λmax
EtOH
 nm (log ε) 208 (4.450), 236 (4.186), 276 (3.988);  λmax /cm
-1
 (film) 
2928 (m), 2856 (m), 1698 (s, C=O), 1163 (vs), 993 (s), 834 (vs), 773 (vs), 699 (vs); 
1
H 
NMR (400 MHz, CDCl3, 20 °C): δH 0.03 (3H, s, MeSi ), 0.04 (3H, s, MeSi ), 0.88 (9H, s, 
Me3CSi), 1.13 (3H, d, J 6, MeCHOSi), 2.17-2.30 (2H, m, CH2CHOSi), 1.13 (2H, t, J  7, 
CH2CHPh), 3.84 (1H, q,  J 6, CHOSi), 5.10 (1H, dd, J 14 & 7,  CHPh), 5.23 (1H, ddd, J  
18, 11 & 7, =CH), 5.74 (1H, dt, J  15 & 7, =CH), 6.07-6.29 (3H, m, =CH), 6.33 (1H, dd, J  
14 & 11, =CH), 6.64 (1H, d brd, J  7, NH), 7.27- 7.33 (3H, m, H-2ʹ, H-4ʹ & H-6ʹ), 7.35-
7.39 (2H, m, H-3ʹ & H-5ʹ); 13C NMR (101 MHz, CDCl3): δc -4.7 (MeSi), -4.6 (MeSi), 18.1 
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(Me3CSi), 23.5 (MeCHOSi), 25.8 (Me3CSi), 33.5 (CH2Ph), 43.2 (CH2CHOSi), 68.5 
(CHOSi), 124.8 (C-4ʹ), 126.4 (C-2ʹ & C-6ʹ), 128.1 (=CH), 128.9 (C-3ʹ & C-5ʹ), 132.2 
(=CH), 132.6 (=CH), 133.1 (=CH), 134.7 (=CH), 135.1 (=CH), 139.3 (C-1ʹ, quaternary), 
155.3 (C=O); 
19
F (376 MHz, CDCl3) δF -75; LRMS (TOF AP
+
): m/z (rel. int.) 391.3 (MH
+
-
C6H5, 100%); LRMS (ES
+
): m/z (rel. int.) 321.3 (M-Me-OTBS, 100%); HRMS (TOF ES
-
): 
Acc. MS calc. for C25H35NO2SiF3
+
 [M-H]
+
, 466.2389, found 466.2321. 
 
   
 (1R,3Z)-2,2,2-Trifluoro-N-(4-iodo-1-phenylbut-3-enyl)acetamide 276 
 
 
To a stirred solution of substrate 258 (110 mg, 0.30 mmol) in CHCl3 (1 mL) at 0 ºC was 
added trifluoroacetic anhydride (0.17 mL, 1.18 mmol). The reaction mixture was stirred at 
room temperature for 3 h, then diluted with toluene (5 mL) and evaporated to give the 
crude product which purified by silica gel column chromatography (EtOAc : petroleum 
ether, 1 : 9, as an eluent) to give the desired product 276 (73 mg, 67%) as a white solid: Mp 
84 – 86 ˚C; Rf  0.1 (hexane : EtOAc, 19 : 1);  C12H11F3NIO requires C, 39.05; H, 3.00; N, 
3.79% found C, 37.62; H, 2.81; N, 3.49%; λmax /cm
-1
 (film) 2924 (m), 1702 (s, C=O), 1644 
(s), 1162 (vs), 698 (vs);  [α]21D -18.4 (c 0.04, CHCl3); 
1
H NMR (400 MHz, CDCl3, 20 °C): 
δH 2.71-2.85 (2H, m, CH2CHPh), 5.19 (1H, dd, J 8, 7, CHPh), 6.15 (1H, dd, J  14, 7, =CH), 
6.42 (1H, dt, J 7 & 1.2, =CHI), 5.56-6.59 (1H, brd, N-H), 7.30-7.36 (3H, m, H-4ʹ, H-2ʹ & 
H-6ʹ), 7.38-7.42 (2H, m, H-3ʹ & H-5ʹ);  
13
C NMR (101 MHz, CDCl3): δc 40.5 (CH2Ph), 52.8 
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(CHPh), 86.8 (=CHI), 126.4 (C-4ʹ), 128.5 (C-2ʹ & C-6ʹ), 129.1 (C-3ʹ & C-5ʹ), 135.2 
(=CHCH2), 138.9 (C-1ʹ, quaternary), 156.7 (C=O); 
19
F (376 MHz, CDCl3): δF  -75.67; 
LRMS (ES): m/z (rel. int.) 292.7 (MH
+
-C6H5, 100%); LRMS (ES
+
): m/z (rel. int.) 392.1 
(MNa
+
, 100%); HRMS (TOF AP
+
): Acc. MS calc. for C9H12NOF3NaI
+
 [M+Na]
+
, 
391.9735; found 391.9742. 
 
Trifluoromethyl (1R,3Z,5E,7E,10RS)-10-tert-butyldimethylsiloxy-1-phenylundeca-
3,5,7-trienylcarbamate 273
 
 
 
 
To a dried Schlenk tube under Ar was added alkenyl iodide 276 (135 mg, 0.85 mmol), 
dialkenyl boronate 175 (331 mg, 0.94 mmol), DMF (12 mL), H2O (1.2 mL), and Ba(OH)2 
(175 mg, 1.02 mmol ). The mixture was degassed using the freeze-pump-thaw method (3 x) 
and Pd(dppf) Cl2.CH2Cl2 (35 mg, 0.042 mmol) was added. The mixture was again degassed 
using the freeze-pump-thaw method (3 x), heated at 45 ºC for 18 h before being diluted 
with Et2O (20 mL) and passing through Celite. After washing with brine (25 mL), the 
aqueous layer was extracted with Et2O (2 x 20 mL). The organic layer was washed with 
brine (2 x 20 mL), dried (MgSO4) and evaporated to give crude product as brown oil. 
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Purification by silica gel chromatography (EtOAc : petroleum ether, 1 : 9, as eluent) gave 
the desired product 273 as a yellow oil (261 mg, 65%); which showed identical 
spectroscopic properties to those previously reported. 
 
 
Trifluoromethyl (1R,3Z, 5E,7E,10RS)-10-hydroxy-1-phenylundeca-3,5,7-
trienylcarbamate 277 
 
 
 
To a solution of 273 (136 mg, 0.384 mmol) in methanol (6 mL) was added DOWEX W8 
(136 mg). The reaction mixture left to stir under argon at rt for 42 hours, then diluted with 
ethyl acetate (25 mL), filtered and evaporated. Purification by SiO2 chromatography 
(EtOAc : petroleum ether,  2 : 3, as eluent) gave the desired product 277 as yellow oil (38 
mg, 31%); Rf  0.71 (hexane : EtOAc, 4 : 1); [α]
21
D -500° (c 1.6, CHCl3); UV λmax
EtOH
 nm 
(log ε) 208 (4.514), 236 (4.231), 272 (4.035), 328 (3.283);   λmax /cm
-1
 (film) 3292 (br, OH), 
2928 (m), 2856 (m), 1698 (s, C=O), 1163 (vs), 993 (s), 834 (vs), 773 (vs), 699 (vs); δH  
(400 MHz, CDCl3) 1.18-1.12 (3H, m, MeCHOH), 2.19-2.31 (2H, m, CH2CHOH), 2.68 
(1H, t, J  7, CHHCHPh), 2.79 (1H, q, J  7, CHHCHPh), 3.84 (1H, q,  J 6, CHOH), 5.10 
(1H, dt, J 15 & 7,  CHPh), 5.26 (1H, ddd, J  18, 11 & 3, =CH), 5.73 (1H, dt, J  14 & 7, 
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=CH), 6.09-6.26 (3H, m, =CH), 6.36 (1H, dd, J  14 & 2, =CH), 6.95 (1H, brd, NH), 7.26-
7.32 (3H, m, H-2ʹ, H-4ʹ & H-6ʹ), 7.34-7.38 (2H, m, H-3ʹ & H-5ʹ); 13C NMR (101 MHz, 
CDCl3): δc 22.7 (MeCHOH), 33.5 (CH2Ph), 42.6 (CH2CHOH), 67.4 (CHOH), 124.7 
(=CH), 125.6 (=CH), 126.6 (C-4ʹ), 126.4 (C-2ʹ & C-6ʹ), 128.1 (=CH), 128.7 (C-3ʹ & C-5ʹ), 
132.2 (=CH), 132.6 (=C-), 133.2 (=CH), 134.3 (=CH), 134.4 (=CH), 139.3 (C-1ʹ, 
quaternary), 156.4 (C=O); 
19
F (376 MHz, CDCl3) δF  -75.73; LRMS (ES
+
): m/z (rel. int.) 
392.5 (MHK
+
, 35%), 391.6 (MK
+
, 100%); HRMS (TOF AP
+
): Acc. MS calc. for 
C19H21NO2F3
+
 [M-H]
+
, 352.1524; found 352.1513. 
 
  
(1R, 3Z)-2-(4-Iodo-1-phenylbut-3-enyl)isoindoline-1,3-dione 279 
 
 
 
To Boc-alkenyl iodide 258 (226 mg, 0.560 mmol) in DCM (0.9 mL) was added TFA (0.9 
mL) at 0˚C. After 20 min of stirring at 0˚C, the TFA salt was trapped with toluene (3 x 5 
mL). The TFA salt 278 (320 mg, 0.827 mmol) was then suspended with phthalic anhydride 
(245 mg, 0.654 mmol) in toluene (14 mL) at rt, treated with triethylamine (0.58 mL, 4.133 
mmol) and left to warm to rt, diluted with ethyl acetate (25 mL) and washed with brine (20 
mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL) and the combined 
organic extracts were washed with brine (20 mL), dried (MgSO4) and evaporated. The 
crude product was purified by SiO2 column chromatography (EtOAc : petroleum ether, 1 : 
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4, as eluent) to give the desired product 279 as a thick white oil (231 mg, 95%); [α]21D -48° 
(c 0.02, CHCl3); λmax/cm
-1
 (film) 2919 (m), 1770 (m), 1706 (vs, C=O), 1384 (s), 1350 (s), 
1330 (s), 717 (vs), 696 (s); 
1
H NMR (400 MHz, CDCl3, 20 °C): δH 3.18 (1H , dtd, J 14.8, 
6.6, 1.5, CHCHPh), 3.33 -3.49 (1H, m, CHCHPh), 5.51 (1H, dd, J 9.7, 6.9, CHPh), 6.18 
(1H , dd, J 13.9, 6.9, =CH), 6.33 (1H , dt, J 7.5, 1.3, =CHI), 7.27-7.30 (1H, m, H-4ʹ), 7.32-
7.36 (2H, m, H-2ʹ & H-6ʹ), 7.55-7.57 (2H, m, H-3ʹ & H-5ʹ), 7.69 (2H, dd, J 5.5, 3.0, H-2ʹʹ 
& H-5ʹʹ), 7.81 (2H, dd, J 5.5, 3.0, H-3ʹʹ & H-4ʹʹ); 
13
C NMR (101 MHz, CDCl3): δc 36.54 
(CH2Ph), 53.23 (CHPh), 85.39 (=CHI), 128.07 (C-4ʹ), 128.09 (C-2ʹ & C-6ʹ), 128.58 (C-3ʹ 
& C-5ʹ), 131.75 (C-1ʹʹ, C-6ʹʹ, quaternary), 133.99 (C-3ʹʹ, C-4ʹʹ), 137.11 (=CHCH2), 138.54 
(C-1ʹ, quaternary), 168.09 (C=O); LRMS (EI): m/z (rel. int.) 276 (M-I, 100%); HRMS 
(TOF ES
+
): Acc. MS calc. for C18H15NO2I
+
 [M+H]
+
, 404.0148; found 404.0140. 
   
N-Phthalimidyl (1R,3Z,5E,7E,10RS)-10-tert-butyldimethylsiloxy-1-phenylundeca-
3,5,7-trienylamine
  
280 
 
 
To a dried Schlenk tube under argon were added Z-alkenyl iodide 279 (190 mg, 0.47 
mmol), dialkenyl boronate 175 (183 mg, 0.52 mmol) and Ba(OH)2 (97 mg, 0.57 mmol) in 
DMF (8 mL) and H2O (0.4 mL). The mixture was degassed using the freeze-pump-thaw 
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method (3 x), and Pd(dppf)Cl2.CH2Cl2 (23 mg, 0.021 mmol) was added. The mixture was 
again degassed using the freeze-pump-thaw method (3 x ) and stirred vigorously at room 
temperature for 23 h before being diluted with Et2O (25 mL), passing through Celite, and 
washing with brine (25 mL). The aqueous layer was extracted with Et2O (2 x 20 mL) and 
the combined organic extracts were washed with brine (20 mL), dried (MgSO4) and 
evaporated to give crude product as a yellow oil. Purification by SiO2 chromatography 
(EtOAc : petroleum ether, 1 : 9, as eluent) gave the desired product 280 as yellow oil (87 
mg, 37%); [α]21D 177.7° (c 0.07, CHCl3); UV λmax
EtOH
 nm (log ε) 208 (4.535), 232 (4.263), 
272 (4.069);  λmax /cm
-1
 (film) 2928 (s), 2855 (m), 1710 (s, C=O), 1471 (m), 1385 (m), 
1253 (m), 994 (s), 718 (vs); δH  (400 MHz, CDCl3) 0.05 (3H, s, MeSi ), 0.06 (3H, s, MeSi ), 
0.90 (9H, s, Me3CSi), 1.14 (3H, d, J 6.1, MeCHOSi), 1.41 (9H, s, Me3CO), 2.17-2.31 (2H, 
m, CH2CHOSi), 3.08-3.13 (1H, m, CHHCHPh), 3.57-3.61 (1H, m, CHHCHPh), 3.82-3.87 
(1H, m, CHOSi), 5.35 (1H, dd, J 18 & 10,  CHPh), 5.44 (1H, dd, J  10 & 4, =CH), 5.64-
5.73 (1H, m, =CH), 6.03-6.16 (3H, m, =CH), 6.44 (1H, dt, J 14 & 11, =CH), 7.27-7.32 (1H, 
m, H-4ʹ), 7.34-7.38 (2H, m, H-2ʹ & H-6ʹ), 7.54-7.57 (2H, m, H-3ʹ & H-5ʹ), 7.68 (2H, dd, J 
5.4 & 2.4, H-2ʹʹ & H-5ʹʹ), 7.80 (2H, dd, J 5.4 & 2.4, H-3ʹʹ & H-4ʹʹ); 
13
C NMR (101 MHz, 
CDCl3): δc -4.7 (MeSi), -4.5 (MeSi), 18.1 (Me3CSi), 23.5 (MeCHOSi), 25.7 (Me3CSi), 29.7 
(CH2CHPh), 43.2 (CH2CHOSi), 54.6 (CHPh), 68.6 (CHOSi), 125.8 (=CH), 126.3 (=CH), 
128.0 (C-4ʹ), 128.1 (C-2ʹ & C-6ʹ), 128.5 (C-3ʹ & C-5ʹ), 131.6 (=CH), 131.8 (C-1ʹʹ, C-6ʹʹ, 
quaternary), 132.1 (=CH), 132.4 (=CH), 132.5 (=CH), 133.8 (C-3ʹʹ, C-4ʹʹ), 134.0 
(=CHCH2), 139.1 (C-1ʹ, quaternary), 168.2 (C=O); ); LRMS (ESI): m/z (rel. int.) 524.3 
(MNa
+
, 100%). 
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